

2031 OXIDOREDUCTASE

Field of the invention

The present invention relates to a method of screening for an anti-fungal agent, to fungal 5 2031 oxidoreductase (2031 OR) enzymes and to diagnosis and therapy of fungal infections.


Background of the invention

Oxidoreductases are a major class of enzymes (EC 1) that catalyse oxidation-reduction 10 (redox) reactions. Redox reactions involve the transfer of reducing equivalents, in the form of electrons or hydrogen atoms, between molecules, i.e., from an electron donor (or reductant) to an electron acceptor (or oxidant). There are many different types of oxidoreductase important for many cellular processes from respiration to protein folding.

The NADH:flavin oxidoreductase /NADH oxidase family of enzymes (InterPro 15 reference IPR001155) contains approximately 263 members mostly of bacterial or yeast origin but with some plant and nematode members. Members of this family use flavin mononucleotide (FMN) or flavin adenine dinucleotide (FAD) as a tightly bound prosthetic group. The flavin prosthetic group can exist in an oxidised (FMN or FAD) or a reduced form (FMNH₂ or FADH₂). These oxidoreductases use the reduced form of nicotinamide 20 adenine dinucleotide (NADH) or nicotinamide adenine dinucleotide phosphate (NADPH) as the reductant. A variety of substrates can act as oxidants in the redox reaction.

Old Yellow Enzyme (OYE) is the oldest known member of this family of oxidoreductases (reviewed in Williams and Bruce, 2002, *Microbiology* 148, 1607-1614). OYE1 (EC 1.6.99.1) was isolated from brewer's bottom yeast by Warburg & Christian 5 (1932, *Naturwissenschaften* 20, 688) and was the first enzyme for which a cofactor was shown to be required (Theorell, 1935, *Biochem. Z.* 275, 344-346). This yellow cofactor was found to be riboflavin 5'-phosphate (also known as flavin mononucleotide, FMN). There are 2 OYES known in *Saccharomyces cerevisiae* (OYE2 & OYE3) and 2 in 0 *Schizosaccharomyces pombe*. A great deal is known about the biochemical mechanism and structure of the enzyme, however, the precise physiological role of the enzyme remains to be elucidated.

OYE has NADPH dehydrogenase activity (see reaction 1 below). The reduced enzyme catalyses the reduction of α/β -unsaturated carbonyl compounds including cyclohexenone (see reaction 2), duroquinone, menadione and N-ethylmaleimide.



10 It has been speculated that OYE may be involved in sterol metabolism (Stott et al, 1993, J. Biol. Chem. 268: 6097-6106) or may be part of the antioxidant defence machinery involved in detoxification of, for example, lipid peroxidation breakdown products (Kohli & Massey, 1998, J. Biol. Chem. 273, 32763-32770). Neither OYE2 nor OYE3 are essential for *S. cerevisiae*. (<http://genome-www4.stanford.edu/cgi-bin/SGD/locus.pl?locus=S0001222>;

15 <http://db.yeastgenome.org/cgibin/SGD/locus.pl?locus=YPL171C>)

Bacterial members of the NADH:flavin oxidoreductase family include *Escherichia coli* N-ethylmaleimide reductase, *Pseudomonas putida* M10 morphinone reductase, *Enterobacter cloacae* PB2 penterythritol tetranitrate reductase and *Azoarcus evansii* 2-aminobenzoyl-CoA monooxygenase/reductase (Schühle et al., 2001, J. Bacteriol. 183, 5268-5278).

Summary of the invention

The inventors have found a gene for an oxidoreductase of the NADH:flavin oxidoreductase type to be essential for the viability of fungal cells. This finding allows the identification of anti-fungal agents based on their ability to target the oxidoreductase.

The invention provides a new group of oxidoreductases which are herein referred to as 2031 oxidoreductases (2031 ORs) which can be used to screen for anti-fungal agents. In particular 2031 oxidoreductases from *Aspergillus fumigatus*, *Aspergillus nidulans*, 30 *Candida albicans*, *Colletotrichium trifolii*, *Fusarium graminearum* (anamorph *Gibberella*

zeae) *Fusarium sporotrichoides*, *Magnaporthe grisea*, *Neurospora crassa*, *Schizosaccharomyces pombe* and *Ustilago maydis* (see Table I) are provided. 2031 OR defines a novel set of oxidoreductases, related to but distinct from OYE and its close relatives, which are essential for the viability of fungal cells.

5

Accordingly the invention provides the following:

- a method of identifying an anti-fungal agent which targets an essential protein or gene of a fungus comprising contacting a candidate substance with

(i) a NADH:flavin oxidoreductase protein which comprises the sequence shown by

10 SEQ ID NO:3,

(ii) a NADH:flavin oxidoreductase protein which is a homologue of (i) and which comprises the sequence shown by SEQ ID NO: 8, 12, 14, 19, 24, 42, 44, 83 or 85,

(iii) a protein which has 50% identity with (i) or (ii),

(iv) a protein comprising a fragment of (i), (ii) or (iii) which fragment has a length of 15 at least 50 amino acids,

(v) a polynucleotide that comprises sequence which encodes (i), (ii), (iii) or (iv),

(vi) a polynucleotide comprising sequence which has at least 70% identity with the coding sequence of (v),

and determining whether the candidate substance binds or modulates (i), (ii), (iii), (iv), (v) 20 or (vi), wherein binding or modulation of (i), (ii), (iii), (iv), (v) or (vi) indicates that the candidate substance is an anti-fungal agent,

- use of (i), (ii), (iii), (iv), (v) or (vi) as defined above to identify or obtain an anti-fungal agent,

- use of an anti-fungal agent identified by the method of the invention in the manufacture 25 of a medicament for prevention or treatment of fungal infection,

- a method of detecting the presence of a fungus in a sample comprising detecting the presence in the said sample of a protein or polynucleotide of the invention,

- an isolated protein or polynucleotide of the invention,

- an organism which is transgenic for a polynucleotide of the invention,

- an organism which has been genetically engineered to render a polynucleotide or protein 30 of the invention non-functional or inhibited.

- an antibody which is specific for a protein of the invention,
- a method for preventing or treating a fungal infection comprising administering an anti-fungal agent identified by the screening method of the invention, and
- a fungus which has been killed, or whose growth has been impaired, by inhibition of the expression or activity of a protein or polynucleotide of the invention.

Detailed description of the invention

As mentioned above the invention relates to use of particular protein and polynucleotide sequences (termed "proteins of the invention" and "polynucleotides of the invention" 10 herein) which are of, or derived from, fungal oxidoreductase proteins and polynucleotides (including homologues and/or fragments of the fungal oxidoreductase proteins and polynucleotides) to identify anti-fungal agents.

As used herein, the term "oxidoreductase" ("OR") may be defined as an enzyme or 15 which is capable of catalysing an oxidation or reduction reaction. The protein of the invention may have an oxidation or reduction activity, such any such activity mentioned herein. The ORs of the invention generally fall within classification EC1 of the enzyme commission.

An essential fungal gene may be defined as one which, when disrupted genetically 20 (for example when not expressed) in a fungus, prevents survival or significantly retards growth of the cell on minimal or defined medium, or in guinea pigs, mice, rabbits or rats infected with the fungus. In one embodiment the protein of the invention is able to complement such an effect of the genetic disruption. Thus the protein may cause survival (viability) of a fungal cell which does not express its native 2031 oxidoreductase.

A protein or polynucleotide of the invention (or a fungal "2031 OR" gene, nucleic 25 acid or protein) may be defined by similarity in sequence to a another member of the family. As mentioned above this similarity may be based on percentage identity (for example to the sequences shown in the sequence listing).

A protein or polynucleotide of the invention may comprise one or more of the motifs defined by regions 1 - 11 of Figures 1 and 2 (marked at the top of the Figures) of any of the 30 sequences shown. Thus a protein of the invention may comprise one or more of motifs 1 – 11 as shown for SEQ ID NO:3 and a polynucleotide of the invention may comprise one or

more of motifs 1 – 11 as shown for SEQ ID NO:1.

Typically the motif is present in substantially the same location as the equivalent location shown in Figure 1 or 2. The equivalent location can be deduced, for example, using any suitable algorithm mentioned herein. In one embodiment the protein or 5 polynucleotide also comprises sequence flanking the motif as shown in Figures 1 or 2 such as sequences of length at least 10, 20 or 30 amino acids/nucleotides flanking the N terminal side and/or C terminal side, or 5' and/or 3' side, of the motif; or sequence which has percentage identity with the flanking sequence.

The protein of the invention typically comprises at least 2, 3, 5, 8 or 11 of the motifs 10 shown in Figures 1 and 2. The protein preferably comprises at least motif no.6 and/or motif no.9.

The protein or polynucleotide of the invention may align with other 2031 OR polynucleotides or proteins (as shown in SEQ ID Nos. 1-44 and 82-85) showing a greater identity to these than to Old Yellow Enzyme family polynucleotides or proteins

15 The protein or polynucleotide of the invention typically clusters with other 2031 OR polynucleotides or proteins (as shown in SEQ ID Nos. 1-44 and 82-85) rather than Old Yellow Enzyme family polynucleotides or proteins after phylogenetic analysis, for example with a bootstrap value of greater than 60%.

20 In one embodiment the protein of the invention has a sequence which matches PFAM profile “oxidored FMN”, or INTERPRO profile IPR001155 (for example with an Evalue of e-50 or less) and is closer to a 2031 OR shown in any one of SEQ ID Nos. 1-44 and 82-85 than to Old Yellow Enzyme family proteins.

25 The protein or polynucleotide of the invention may be in isolated form (such as non-cellular form), for example when used in the method of the invention. Preferably, the isolated polynucleotide comprises a 2031 OR gene. Preferably, the isolated protein comprises a 2031 OR. The polynucleotide may comprise native, synthetic or recombinant polynucleotide, and the protein may comprise native, synthetic or recombinant protein. The polynucleotide or protein may comprise combinations of native, synthetic or recombinant polynucleotide or protein, respectively. The polynucleotides and proteins of the invention 30 may have a sequence which is the same as, or different from, naturally occurring 2031 OR polynucleotides and proteins.

It is to be understood that the term "isolated from" may be read as "of" herein. Therefore references to polynucleotides and proteins being "isolated from" a particular organism include polynucleotides and proteins which were prepared by means other than obtaining them from the organism, such as synthetically or recombinantly.

5 Preferably, the polynucleotide or protein, is isolated from a fungus, more preferably a filamentous fungus, even more preferably an Ascomycete.

Preferably, the polynucleotide or protein, is isolated from an organism selected from *Aspergillus*; *Blumeria*; *Candida*; *Colletotrichium*; *Cryptococcus*; *Encephalitozoon*; *Fusarium*; *Leptosphaeria*; *Magnaporthe*; *Mycosphaerella*; *Neurospora*; *Phytophthora*; *10 Plasmopara*; *Pneumocystis*; *Pyricularia*; *Pythium*; *Puccinia*; *Rhizoctonia*; *Schizosaccharomyces*, *Trichophyton*; and *Ustilago*.

Preferably, the polynucleotide or protein, is isolated from an organism independently selected from a group of genera consisting of *Aspergillus*, *Candida*, *Colletotrichium*, *Fusarium*, *Magnaporthe*, *Mycosphaerella*, *Neurospora*, *Schizosaccharomyces* and *15 Ustilago*.

Preferably, the polynucleotide or protein, is isolated from an organism selected from the species *Aspergillus flavus*; *Aspergillus fumigatus*; *Aspergillus nidulans*; *Aspergillus niger*; *Aspergillus parasiticus*; *Aspergillus terreus*; *Blumeria graminis*; *Candida albicans*; *Candida cruzei*; *Candida glabrata*; *Candida parapsilosis*; *Candida tropicalis*; *20 Colletotrichium trifolii*; *Cryptococcus neoformans*; *Encephalitozoon cuniculi*; *Fusarium graminarium*; *Fusarium solani*; *Fusarium sporotrichoides*; *Leptosphaeria nodorum*; *Magnaporthe grisea*; *Mycosphaerella graminicola*; *Neurospora crassa*; *Phytophthora capsici*; *Phytophthora infestans*; *Plasmopara viticola*; *Pneumocystis jiroveci*; *Puccinia coronata*; *Puccinia graminis*; *Pyricularia oryzae*; *Pythium ultimum*; *Rhizoctonia solani*; *25 Schizosaccharomyces pombe*; *Trichophyton interdigitale*; *Trichophyton rubrum*; and *Ustilago maydis*.

Preferably, the polynucleotide or protein, is isolated from an organism selected from *Aspergillus fumigatus*; *Aspergillus nidulans*, *Candida albicans*, *Colletotrichium trifolii*, *Fusarium graminearum*, *Fusarium sporotrichoides*, *Magnaporthe grisea*, *Mycosphaerella graminicola*, *Neurospora crassa*, *Schizosaccharomyces pombe* and *Ustilago maydis*.

The polynucleotide, and preferably the protein, may be isolated from *A. fumigatus* AF293.

5 Table I. 2031 OR sequences claimed and their relationship to sequences given in the sequence listing.

	gDNA/EST ¹	Coding sequence(cDNA/mRNA) w/o UTRs ²	Protein
<i>A. fumigatus</i> Oxidoreductase 2031	SEQ ID No. 1: 299-469, 520-1618	SEQ ID No. 2: 115-1384	SEQ ID. No. 3
<i>A. fumigatus</i> Oxidoreductase 4929	SEQ ID No. 4: 1-180, 267-1352	SEQ ID No. 5: 1-1266	SEQ ID No. 6
<i>A. fumigatus</i> Oxidoreductase 1495	SEQ ID No. 7: 1-1329	SEQ ID No. 7: 1-1329	SEQ ID No. 8
<i>A. nidulans</i> 1_112	SEQ ID No. 9: 1-1269	SEQ ID No. 9: 1-1269	SEQ ID No. 10
<i>C. albicans</i> 2431	SEQ ID No. 11: 1-1299	SEQ ID No. 11 1-1299	SEQ ID No. 12
<i>C. albicans</i> 2464	SEQ ID No. 13: 1-1110	SEQ ID No. 13: 1-1110	SEQ ID No. 14
<i>N. crassa</i> NCU07452.1	SEQ ID No. 15: 1-1305	SEQ ID No. 15: 1-1305	SEQ ID No. 16
<i>N. crassa</i> Oxidoreductase NCU08900	SEQ ID No. 17: 1-924,1015- 1362,1435-1476	SEQ ID No. 18: 1-1314	SEQ ID No. 19
<i>M. grisea</i> MG04569.3 (pred gene)	SEQ ID No. 20: 1-726, 810- 1412	SEQ ID No. 21: 1-1329	SEQ ID No.22
<i>S. pombe</i> T39956	SEQ ID No. 23: 1-1188	SEQ ID No. 23: 1-1188	SEQ ID No. 24
<i>C. trifolii</i> (EST assembly)	SEQ ID No. 25: 130-777	SEQ ID No. 26: 1-645 ⁽³⁾	SEQ ID No. 27
<i>F. sporotrichoides</i> FsCon[0063] (ESTs)	SEQ ID No. 28: 103-803	SEQ ID No. 29: 1-701	SEQ ID No. 30
<i>F. sporotrichoides</i> FsCon[0237] (ESTs)	SEQ ID No. 31: 76-631 (rev comp)	SEQ ID No. 32: 1-556	SEQ ID No.33
<i>F. sporotrichoides</i> FsCon[0458] (ESTs)	SEQ ID No. 34: 174-657	SEQ ID No. 34: 174-657	SEQ ID No.35

<i>F. graminearum</i> 15771741 (EST)	SEQ ID No. 36: 1-744	SEQ ID No. 37: 1-742 ⁽⁴⁾	SEQ ID No.38
<i>F. graminearum</i> FG00074.1	SEQ ID No. 82: 1-1326	SEQ ID No. 82: 1-1326	SEQ ID No. 83
<i>M. graminicola</i> mg[0281] (EST)	SEQ ID No. 39: 1-647	SEQ ID No. 39: 1-647	SEQ ID No.40
<i>M. graminicola</i> mga0328f (EST)	SEQ ID No. 41: 1-560	SEQ ID No. 41: 1-560	SEQ ID No.42
<i>M. grisea</i> MG03823.3	SEQ ID No. 43: 1-1254	SEQ ID No. 43: 1-1254	SEQ ID No.44
<i>Ustilago maydis</i> Contig 1.2	SEQ ID No. 84: 1-1350	SEQ ID No. 84: 1-1350	SEQ ID No. 85

⁽¹⁾Numbers after SEQ ID Nos. correspond to bases of genomic DNA encoding the protein.

⁽²⁾RNA sequences are given in the sequence listing with Thymidine (T), although it is understood that *in vivo* Uridine (U) would be present.

⁽³⁾NA one-base deletion at position 690 of the EST (SEQ ID No. 22) is required to give the

5 best predicted cDNA/protein.

⁽⁴⁾Two single base deletions are required to optimise translation.

Bioinformatics analysis was carried out to identify functionally important regions within the fungal 2031 ORs. The 2031 ORs are related to but distinct from the "Old Yellow Enzyme" (OYE) group of yeast enzymes, which also includes ergosterol-binding protein of *Candida albicans*. Comparison of the 2031 ORs with crystal structures of OYE family proteins identified highly conserved residues responsible for the catalytic function of these enzymes. However, the comparisons also identified seven clusters of residues conserved in 2031 enzymes but not OYE enzymes which flanked the substrate binding site and were therefore implicated in determining substrate specificity (regions 2, 4, 6, 7, 8, 10, and 11 in Figures 1 and 2, and Example 4 hereinafter). Four further conserved clusters of residues were identified which, while not predicted to be involved in catalysis, were conserved in 2031 but not OYE and so also distinguish 2031 ORs from OYEs (regions 1, 3, 5, and 9 in Figures 1 and 2, and Example 4 hereinafter).

20 Variants of the above mentioned polynucleotides and proteins are also provided, and are discussed below.

In one embodiment, the protein of the invention may comprise an amino acid sequence substantially as set out and independently selected from regions 1 - 11 of any of SEQ ID Nos 3, 6, 8, 10, 12, 14, 16, 19, 22, 24, 27, 30, 33, 35, 38, 40, 42, 44, 83 or 85 as given in Figure 1, or variants thereof. At least one region or motif may be functional.

5 The polynucleotide of the invention may comprise DNA, such as genomic DNA. The polynucleotide may comprise a sequence substantially as set out and independently selected from regions 1 - 11 of any of SEQ ID Nos. 1, 4, 7, 9, 11, 13, 15, 17, 20, 23, 25, 28, 31, 34, 36, 39 41, 43, 82 or 84 as given in Figure 2, or complements, or variants thereof.

10 Preferably, the polynucleotide encodes a fungal 2031 OR protein which comprises substantially the amino acid sequences SEQ ID Nos 3, 6, 8, 10, 12, 14, 16, 19, 22, 24, 27, 30, 33, 35, 38, 40, 42, 83 or 85 or a variant thereof.

15 The polynucleotide may comprise RNA, preferably mRNA, preferably spliced mRNA. Preferably, the polynucleotide comprises substantially the sequence shown as SEQ ID Nos 2, 5, 7, 9, 11, 13, 15, 18, 21, 23, 26, 29, 32, 34, 36, 37, 39, 41, 43, 82 or 84 or a complement, or a variant thereof.

Preferably, the protein comprises substantially the sequences SEQ ID Nos. 3, 6, 8, 10, 12, 14, 16, 19, 22, 24, 27, 30, 33, 35, 38, 40, 42, 44, 83 or 85 or a variant thereof.

20 Preferably, the protein is encoded by the regions of sequences SEQ ID Nos. 1, 4, 7, 9, 11, 13, 15, 17, 20, 23, 25, 26, 28, 29, 31, 34, 36, 39, 41, 43, 82 or 84 as described in Figure 1. in the column "gDNA/EST" in Table I, or a complement, or a variant thereof.

25 The polynucleotide may comprise substantially a nucleotide sequence region or motif independently selected from at least one of regions 1-11 from at least one of the sequences SEQ ID Nos. 1, 2, 4, 5, 7, 9, 11, 13, 15, 17, 18, 20, 21, 23, 25, 26, 28, 29, 31, 32, 34, 36, 37, 39, 41, 43, 82 or 84, as given in Figure 2, or a complement, or a variant thereof.

Preferably, the isolated polynucleotide comprises substantially a nucleotide sequence independently selected from the regions and sequences given in the column "gDNA/EST" in Table I.

30 Preferably, the protein is encoded by a polynucleotide which polynucleotide comprises substantially a sequence independently selected from at least one of the the regions and sequences given in the column "gDNA/EST" in Table I, or a complement or, a variant thereof.

By the term “native amino acid/polynucleotide/protein”, is meant an amino acid, polynucleotide or protein produced naturally from biological sources either *in vivo* or *in vitro*.

By the term “synthetic amino acid/polynucleotide/protein”, is meant an amino acid, 5 polynucleotide or protein which has been produced artificially or *de novo* using a DNA or protein synthesis machine known in the art.

By the term “recombinant amino acid/polynucleotide /protein”, is meant an amino acid, polynucleotide or protein which has been produced using recombinant DNA or protein technology or methodologies which are known to the skilled technician.

10 The term “variant”, and the terms “substantially the amino acid/polynucleotide/protein sequence” are used herein to refer to related sequences. As discussed below such related sequences are typically homologous to (share percentage identity with) a given sequence, for example over the entire length of the sequence or over a portion of a given length. The related sequence may also be a fragment of the sequence 15 or of a homologous sequence. A variant protein may be encoded by a variant polynucleotide.

By the term “variant”, and the terms “substantially the amino acid/polynucleotide/protein sequence”, we mean that the sequence has at least 30%, preferably 40%, more preferably 50%, and even more preferably, 60% sequence identity 20 with the amino acid/polynucleotide/protein sequences of any one of the sequences referred to. A sequence which is “substantially the amino acid/polynucleotide/peptide sequence” may be the same as the relevant sequence.

Calculation of percentage identities between different amino acid/polynucleotide/protein sequences may be carried out as follows. A multiple alignment 25 is first generated by the ClustalX program (pairwise parameters: gap opening 10.0, gap extension 0.1, protein matrix Gonnet 250, DNA matrix IUB; multiple parameters: gap opening 10.0, gap extension 0.2, delay divergent sequences 30%, DNA transition weight 0.5, negative matrix off, protein matrix gonnet series, DNA weight IUB; Protein gap parameters, residue-specific penalties on, hydrophilic penalties on, hydrophilic residues 30 GPSNDQERK, gap separation distance 4, end gap separation off). The percentage identity is then calculated from the multiple alignment as $(N/T)*100$, where N is the number of

positions at which the two sequences share an identical residue, and T is the total number of positions compared. Alternatively, percentage identity can be calculated as (N/S)*100 where S is the length of the shorter sequence being compared. The amino acid/polynucleotide/protein sequences may be synthesised *de novo*, or may be native amino acid/polynucleotide/protein sequence, or a derivative thereof.

5 An amino acid/polynucleotide/protein sequence with a greater identity than 65% to any of the sequences referred to is also envisaged. An amino acid/polynucleotide/protein sequence with a greater identity than 70% to any of the sequences referred to is also envisaged. An amino acid/polynucleotide/protein sequence with a greater identity than 10 75% to any of the sequences referred to is also envisaged. An amino acid/polynucleotide/protein sequence with a greater identity than 80% to any of the sequences referred to is also envisaged. Preferably, the amino acid/polynucleotide/protein sequence has 85% identity with any of the sequences referred to, more preferably 90% identity, even more preferably 92% identity, even more preferably 95% identity, even 15 more preferably 97% identity, even more preferably 98% identity and, most preferably, 99% identity with any of the referred to sequences.

The above mentioned percentage identities may be measured over the entire length of the original sequence or over a region of 15, 20, 50 or 100 amino acids/bases of the original sequence. In a preferred embodiment percentage identity is measured with 20 reference to SEQ ID No. 3. Preferably the variant protein has at least 40% identity, such as at least 60% or at least 80% identity with SEQ ID No. 3 or a portion of SEQ ID No. 3.

Alternatively, a substantially similar nucleotide sequence will be encoded by a sequence which hybridizes to the sequences shown in SEQ ID Nos. 1, 2, 4, 5, 7, 8, 9, 11, 13, 15, 17, 18, 20, 21, 23, 25, 26, 28, 29, 31, 32, 34, 36, 37, 39, 41, 43, 82 or 84 or their 25 complements under stringent conditions. By stringent conditions, we mean the nucleotide hybridises to filter-bound DNA or RNA in 6x sodium chloride/sodium citrate (SSC) at approximately 45°C followed by at least one wash in 0.2x SSC/0.1% SDS at approximately 5-65°C. Alternatively, a substantially similar protein may differ by at least 1, but less than 30 5, 10, 20, 50 or 100 amino acids from the sequences shown in SEQ ID Nos. 3, 6, 8, 10, 12, 14, 16, 19, 22, 24, 27, 30, 33, 35, 38, 40, 42, 44, 83 or 85. Such differences may each be additions, deletions or substitutions.

5 Due to the degeneracy of the genetic code, it is clear that any nucleic acid sequence could be varied or changed without substantially affecting the sequence of the protein encoded thereby, to provide a functional variant thereof. Suitable nucleotide variants are those having a sequence altered by the substitution of different codons that encode the same amino acid within the sequence, thus producing a silent change.

10 Other suitable variants are those having homologous nucleotide sequences but comprising all, or portions of, sequence which are altered by the substitution of different codons that encode an amino acid with a side chain of similar biophysical properties to the amino acid it substitutes, to produce a conservative change. For example small non-polar, hydrophobic amino acids include glycine, alanine, leucine, isoleucine, valine, proline, and methionine. Large non-polar, hydrophobic amino acids include phenylalanine, tryptophan and tyrosine. The polar neutral amino acids include serine, threonine, cysteine, asparagine and glutamine. The positively charged (basic) amino acids include lysine, arginine and histidine. The negatively charged (acidic) amino acids include aspartic acid and glutamic acid. Certain organisms, including *Candida* are known to use non-standard codons compared to those used in the majority of eukaryotes. Any comparisons of polynucleotides and proteins from such organisms with the sequences given here should take these differences into account.

20 In accurate alignment of protein or DNA sequences the trade-off between optimal matching of sequences and the introduction of gaps to obtain such a match is important. In the case of proteins, the means by which matches are scored is also of significance. The family of PAM matrices (e.g., Dayhoff, M. et al., 1978, *Atlas of protein sequence and structure*, Natl. Biomed. Res. Found.) and BLOSUM matrices quantitate the nature and likelihood of conservative substitutions and are used in multiple alignment algorithms, 25 although other, equally applicable matrices will be known to those skilled in the art. The popular multiple alignment program ClustalW, and its windows version ClustalX (Thompson et al., 1994, *Nucleic Acids Research*, 22, 4673-4680; Thompson et al., 1997, *Nucleic Acids Research*, 24, 4876-4882) are efficient ways to generate multiple alignments of proteins and DNA.

Use of the Align program is also preferred (Hepperle, D., 2001: Multicolor Sequence Alignment Editor. Institute of Freshwater Ecology and Inland Fisheries, 16775 Stechlin, Germany), although others, such as JalView or Cinema are also suitable.

Calculation of percentage identities between proteins occurs during the generation of 5 multiple alignments by Clustal. However, these values need to be recalculated if the alignment has been manually improved, or for the deliberate comparison of two sequences. Programs that calculate this value for pairs of protein sequences within an alignment include PROTDIST within the PHYLIP phylogeny package (Felsenstein; <http://evolution.gs.washington.edu/phylip.html>) using the "Similarity Table" option as the 10 model for amino acid substitution (P). For DNA/RNA, an identical option exists within the DNADIST program of PHYLIP.

Other modifications in protein sequences are also envisaged and within the scope of the claimed invention, i.e. those which occur during or after translation, e.g. by acetylation, amidation, carboxylation, phosphorylation, proteolytic cleavage or linkage to a ligand.

15 The term "variant", and the terms "substantially the amino acid/polynucleotide/protein sequence" also include a fragment of the relevant polynucleotide or protein sequences, including a fragment of the homologous sequences (which have percentage identity to a specified sequence) referred to above. A polynucleotide fragment will typically comprise at least 10 bases, such as at least 20, 30, 20 50, 100, 200, 500 or 1000 bases. A protein fragment will typically comprise at least 10 amino acids, such as at least 20, 30, 50, 80, 100, 150, 200, 300, 400 or 500 amino acids. The fragments may lack at least 3 amino acids, such as at least 10, 20 or 30 amino acids of the amino acids from either end of the protein.

25 The invention provides a method of screening which may be used to identify modulators of 2031 OR proteins or polynucleotides, such as inhibitors of expression or activity of the proteins or polynucleotides of the invention. In one embodiment of the method a candidate substance is contacted with a protein or polynucleotide of the invention and whether or not the candidate substance binds or modulates the protein or polynucleotide is determined.

30 The modulator may promote (agonise) or inhibit (antagonise) the activity of the protein. A therapeutic modulator (against fungal infection) will inhibit the expression or

activity of protein or polynucleotide of the invention.

The method may be carried out *in vitro* (inside or outside a cell) or *in vivo*. In one embodiment the method is carried out on a cell, or cell culture cell extract. The cell may or may not be a cell in which the polynucleotide or protein is naturally present. The cell may or may not be a fungal cell, or may or may not be a cell of any of the fungi mentioned herein. The protein or polynucleotide may be present in a non-cellular form in the method, thus the protein may be in the form of a recombinant protein purified from a cell.

Any suitable binding or activity assay may be used. Methods which determine whether a candidate substance is able to bind the protein or polynucleotide may comprise providing the protein or polynucleotide to a candidate substance and determining whether binding occurs, for example by measuring the amount of the candidate substance which binds the protein or polynucleotide. The binding may be determined by measuring a characteristic of the protein or polynucleotide that changes upon binding, such as spectroscopic changes. The binding may be determined by measuring reaction substrate or product levels in the presence and absence of the candidate and comparing the levels.

The assay format may be a 'band shift' system. This involves determining whether a test candidate advances or retards the protein or polynucleotide on gel electrophoresis relative to the absence of the compound.

The method may be a competitive binding method. This determines whether the candidate is able to inhibit the binding of the protein or polynucleotide to an agent which is known to bind to the protein or polynucleotide, such as an antibody specific for the protein, or a substrate of the protein.

Whether or not a candidate substance modulates the activity of the protein may be determined by providing the candidate substance to the protein under conditions that permit activity of the protein, and determining whether the candidate substance is able to modulate the activity of the product.

The activity which is measured may be any of the activities of the protein of the invention mentioned herein, such as oxidoreductase activity. In one embodiment the screening method comprising carrying out a redox reaction in the presence and absence of the candidate substance to determine whether the candidate substance inhibits the oxidoreductase activity of the protein of the invention, wherein the redox reaction is

carried out by contacting said protein with NADH or NADPH; and an electron acceptor, under conditions in which in the absence of the candidate substance the protein catalyses reduction of the electron acceptor.

In a preferred embodiment the inhibition of the redox reaction is measured by 5 detecting the amount of NADH or NADPH oxidation, for example by measuring the generation of the oxidised forms of NADH and NADPH spectroscopically. This can be done by measurement at 340nm (see Example 7).

Alternatively, a suitable colourimetric oxidoreductase substrate may be used to 10 measure inhibition, such as methylene blue, phenazine methosulphate or 2, 6-dichlorophenolindophenol.

Suitable candidate substances which can tested in the above methods include 15 antibody products (for example, monoclonal and polyclonal antibodies, single chain antibodies, chimeric antibodies and CDR-grafted antibodies). Furthermore, combinatorial libraries, defined chemical identities, peptide and peptide mimetics, oligonucleotides and natural product libraries, such as display libraries (e.g. phage display libraries) may also be tested. The candidate substances may be chemical compounds. Batches of the candidate substances may be used in an initial screen of, for example, ten substances per reaction, and the substances from batches which show inhibition tested individually.

According to a further aspect of the present invention, there is provided a 20 polynucleotide or protein of the invention for use as a medicament or in diagnosis.

The polynucleotide or protein may be modified prior to use, preferably to produce a derivative or variant thereof. The polynucleotide or protein may be derivatised. The protein may be modified by epitope tagging, addition of fusion partners or purification tags such as 25 glutathione *S*-transferase, multiple histidines or maltose binding protein, addition of green fluorescent protein, covalent attachment of molecules including biotin or fluorescent tags, incorporation of selenomethionine, inclusion or attachment of radioisotopes or fluorescent/non-fluorescent lanthanide chelates. The polynucleotide may be modified by methylation or attachment of digoxigenin (DIG) or by addition of sequence encoding the above tags, proteins or epitopes.

30 Preferably, the medicament is adapted to retard or prevent a fungal infection. The fungal infection may be in human, animal or plant. The polynucleotide or protein may be

used for the development of a drug. The polynucleotide or protein may be used in, or for the generation of, a molecular model of said polynucleotide or said protein.

According to a further aspect of the present invention, there is provided use of a polynucleotide or protein of the invention for the preparation of a medicament for the 5 treatment of a fungal infection.

The polynucleotide or protein may be modified prior to use, preferably to produce a derivative or variant thereof. The polynucleotide or protein may be derivatised. The polynucleotide or protein may not be modified or derivatised.

Preferably, the medicament is adapted to retard or prevent a fungal infection. The 10 treatment may comprise retarding or preventing fungal infection. Preferably, the drug and/or medicament comprises an inhibitor, preferably a 2031 OR inhibitor. Preferably, the drug or medicament is adapted to inhibit expression and/or activity of the polynucleotide or a fragment thereof, and/or the function of the protein or a fragment thereof.

Preferably, the fungal infection comprises an infection by a fungus, more preferably 15 an Ascomycete, and even more preferably, an organism selected from the genera *Aspergillus*; *Blumeria*; *Candida*; *Colletotrichium*; *Cryptococcus*; *Encephalitozoon*; *Fusarium*; *Leptosphaeria*; *Magnaporthe*; *Mycosphaerella*; *Neurospora*; *Phytophthora*; *Plasmopara*; *Pneumocystis*; *Pyricularia*; *Pythium*; *Puccinia*; *Rhizoctonia*; *Schizosaccharomyces*; *Trichophyton*; and *Ustilago*.

20 Preferably, the fungal infection comprises an infection by an organism selected from the genera *Aspergillus*, *Candida*, *Colletotrichium*, *Fusarium*, *Magnaporthe*, *Mycosphaerella* and *Ustilago*.

Preferably, the fungal infection comprises an infection by an organism selected from 25 the species *Aspergillus flavus*; *Aspergillus fumigatus*; *Aspergillus nidulans*; *Aspergillus niger*; *Aspergillus parasiticus*; *Aspergillus terreus*; *Blumeria graminis*; *Candida albicans*; *Candida crucei*; *Candida glabrata*; *Candida parapsilosis*; *Candida tropicalis*; *Colletotrichium trifolii*; *Cryptococcus neoformans*; *Encephalitozoon cuniculi*; *Fusarium graminarium*; *Fusarium solani*; *Fusarium sporotrichoides*; *Leptosphaeria nodorum*; *Magnaporthe grisea*; *Mycosphaerella graminicola*; *Phytophthora capsici*; *Phytophthora infestans*; *Plasmopara viticola*; *Pneumocystis jiroveci*; *Puccinia coronata*; *Puccinia*

graminis; Pyricularia oryzae; Pythium ultimum; Rhizoctonia solani; Trichophyton interdigitale; Trichophyton rubrum; and Ustilago maydis.

Preferably, the fungal infection comprises an infection by an organism selected from the species *Aspergillus fumigatus; Aspergillus nidulans; Candida albicans; Colletotrichium trifolii; Fusarium graminearum; Fusarium sporotrichoides; Magnaporthe grisea; Mycosphaerella graminicola* and *Ustilago maydis*.

According to another aspect of the present invention, there is provided a method of detecting the presence of a fungal infection in an individual, said method comprising:-

- (i) obtaining a sample from an organism; and
- 10 (ii) detecting in the said sample the presence of a polynucleotide or protein of the invention.

The individual may be a person (human) or animal (such as a mammal or bird) or a plant. The fungal infection may arise from infection with an organism selected from the genera *Aspergillus; Blumeria; Candida; Colletotrichium; Cryptococcus; Encephalitozoon; Fusarium; Leptosphaeria; Magnaporthe; Mycosphaerella; Phytophthora; Plasmopara; Pneumocystis; Pyricularia; Pythium; Puccinia; Rhizoctonia; Trichophyton; and Ustilago*

The fungal infection may arise from infection with an organism selected from the species *Aspergillus flavus; Aspergillus fumigatus; Aspergillus nidulans; Aspergillus niger; Aspergillus parasiticus; Aspergillus terreus; Blumeria graminis; Candida albicans; Candida cruzei; Candida glabrata; Candida parapsilosis; Candida tropicalis; Colletotrichium trifolii; Cryptococcus neoformans; Encephalitozoon cuniculi; Fusarium graminarium; Fusarium solani; Fusarium sporotrichoides; Leptosphaeria nodorum; Magnaporthe grisea; Mycosphaerella graminicola; Phytophthora capsici; Phytophthora infestans; Plasmopara viticola; Pneumocystis jiroveci; Puccinia coronata; Puccinia graminis; Pyricularia oryzae; Pythium ultimum; Rhizoctonia solani; Trichophyton interdigitale; Trichophyton rubrum; and Ustilago maydis.*

Preferably, the sample comprises a biological sample which, preferably, comprises nucleic acid and/or protein. In one embodiment of the method the nucleic acid or protein is purified (at least partially) from the sample before the detection is performed.

30 Where the organism is *Aspergillus fumigatus, Aspergillus nidulans* or *Aspergillus niger*, the sample may comprise sputum, bronchoalveolar lavage, urine, respiratory

specimens, endotracheal aspirates, sterile specimens obtained by an invasive procedure such as vitreous tap, tympanocentesis, brain biopsy or aspiration, nasal or sinus specimens, blood, tissue or autopsy.

Where the organism is *Magnaporthe grisea* the sample may comprise rice leaf or rice stem.

Preferably, said detecting of the presence in the said sample of a polynucleotide as defined by the first or third aspect comprises use of at least one oligonucleotide pair adapted to be used for amplification of DNA, preferably genomic, more preferably, fungal genomic DNA. The amplification may be PCR amplification.

Preferably, the PCR amplification employs at least one primer pair comprising a polynucleotide selected from the group consisting of:

Aspergillus fumigatus; SEQ ID Nos 67 and 68 for SEQ ID No. 1; SEQ ID Nos 69 and 70 for SEQ ID No. 4; and SEQ ID Nos 71 and 72 for SEQ ID No. 7.

Candida albicans; SEQ ID Nos 73 and 74 for SEQ ID No. 11.

Magnaporthe grisea; SEQ ID Nos 75 and 76 for SEQ ID No. 20.

Preferably, said detecting comprises subjecting the amplified DNA to size analysis, preferably, electrophoresis and, preferably, comparing the results to a positive control and, preferably, a negative control. Said detecting may also comprise sequencing of the amplified DNA to demonstrate the correct sequence.

Preferably, said detecting of the presence in the said sample of a protein comprises use of a monoclonal or polyclonal antibody directed to part or all of the protein of the invention.

According to a further aspect of the present invention, there is provided a recombinant DNA molecule or vector comprising a polynucleotide of the invention.

The recombinant DNA molecule or vector may comprise an expression cassette. Preferably, the recombinant DNA molecule or vector comprises an expression vector. Preferably, the polynucleotide sequence is operatively linked to an expression control sequence. A suitable control sequence may comprise a promoter, an enhancer etc.

According to another aspect of the present invention, there is provided a cell containing a polynucleotide, recombinant DNA molecule or vector of the invention.

The cell may be transformed or transfected with the polynucleotide, recombinant DNA molecule or vector by suitable means. Preferably, the cell produces a recombinant protein of the invention.

The invention also provides an organism which is transgenic for the polynucleotide of the invention (whose cells may be the same as the cells of the invention mentioned herein). Such an organism is typically a fungus, such as any genera or species of fungus mentioned herein. The organism may be microorganism, such as a bacterium, virus or yeast. The organism may be a plant, animal (including birds and mammals), such as any of the animals mentioned herein.

The organism may be produced by introduction of the polynucleotide of the invention into a cell of the organism, and in the case of a multicellular organism allowing the cell to grow into a whole organism.

According to a further aspect of the present invention, there is provided a cell in which a native polynucleotide or protein of the invention protein is non-functional and/or inhibited. The cell may be of, or present in, a multicellular organism.

The cell may be a mutant cell. The cell is typically a fungal cell, such as of any genera or species of fungus mentioned herein. A preferred means of generating the cell is to modify the polynucleotide of the invention, such that the polynucleotide is non-functional. This modification may be to cause a mutation, which disrupts the expression or function of a gene product. Such mutations may be to the nucleic acid sequences that act as 5' or 3' regulatory sequences for the polynucleotide, or may be a mutation introduced into the coding sequence of the polynucleotide. Functional deletion of the polynucleotide may be, for example, by mutation of the polynucleotide in the form of nucleotide substitution, addition or, preferably, nucleotide deletion.

The polynucleotide may be made non-functional and/or inhibited by:

- (i) shifting the reading frame of the coding sequence of the polynucleotide;
- (ii) adding, substituting or deleting amino acids in the protein encoded by the polynucleotide; or
- (iii) partially or entirely deleting the DNA coding for the polynucleotide and/or the upstream and downstream regulatory sequences associated with the polynucleotide.
- (iv) inserting DNA into the coding or non-coding regions.

A preferred means of introducing a mutation into a polynucleotide is to utilize molecular biology techniques specifically to target the polynucleotide which is to be mutated. Mutations may be induced using a DNA molecule. A most preferred means of introducing a mutation is to use a DNA molecule that has been especially prepared such 5 that homologous recombination occurs between the target polynucleotide and the DNA molecule. When this is the case, the DNA molecule, which may be double stranded, may contain base sequences similar or identical to the target polynucleotide to allow the DNA molecule to hybridize to (and subsequently recombine with) the target.

It is also possible to provide a cell in which the polynucleotide is non-functional 10 and/or inhibited without introducing a mutation into the gene or its regulatory regions. This may be done by using specific inhibitors. Examples of such inhibitors include agents that prevent transcription of the polynucleotide, or prevent translation, expression or disrupt post-translational modification. Alternatively, the inhibitor may be an agent that increases degradation of the gene product (e.g. a specific proteolytic enzyme). Equally, the 15 inhibitor may be an agent which prevents the polynucleotide product from functioning, such as neutralizing antibodies (for instance an anti-2031 OR antibody). The inhibitor may also be an antisense oligonucleotide, or any synthetic chemical capable of inhibiting expression of the gene or the stability and/or function of the protein. The inhibitor may also be a protein which interacts with the 2031 OR to prevent its function. The inhibitor may 20 also be an RNA molecule which causes inhibition by RNA interference. In one embodiment the antisense polynucleotide or RNA molecule which causes RNA interference are examples of polynucleotides of the invention.

According to a further aspect, there is provided an antibody exhibiting 25 immunospecificity for a protein of the invention. The antibody may be used as a diagnostic reagent.

The antibody may be monoclonal or polyclonal, and may be raised in mouse, rat, rabbit, chicken, turkey, horse, goat or donkey. The antibody may be raised against one or all of the proteins together, or may be raised against proteolytic or recombinant fragments.

For the purposes of this invention, the term "antibody", unless specified to the 30 contrary, includes fragments which bind a protein of the invention. Such fragments include Fv, F(ab') and F(ab')₂ fragments, as well as single chain antibodies. Furthermore,

the antibodies and fragment thereof may be chimeric antibodies, CDR-grafted antibodies or humanised antibodies.

Administration

5 The formulation of any of the therapeutic substances (e.g. proteins, polynucleotides or modulators) mentioned herein will depend upon factors such as the nature of the substance and the condition to be treated. Any such substance may be administered in a variety of dosage forms. It may be administered orally (e.g. as tablets, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules), parenterally, 10 subcutaneously, intravenously, intramuscularly, intrasternally, transdermally or by infusion techniques. The substance may also be administered as suppositories. A physician will be able to determine the required route of administration for each particular patient.

Typically the substance is formulated for use with a pharmaceutically acceptable carrier or diluent. The pharmaceutical carrier or diluent may be, for example, an isotonic 15 solution. For example, solid oral forms may contain, together with the active compound, diluents, e.g. lactose, dextrose, saccharose, cellulose, corn starch or potato starch; lubricants, e.g. silica, talc, stearic acid, magnesium or calcium stearate, and/or polyethylene glycols; binding agents; e.g. starches, arabic gums, gelatin, methylcellulose, carboxymethylcellulose or polyvinyl pyrrolidone; disaggregating agents, e.g. starch, 20 alginic acid, alginates or sodium starch glycolate; effervescent mixtures; dyestuffs; sweeteners; wetting agents, such as lecithin, polysorbates, laurylsulphates; and, in general, non-toxic and pharmacologically inactive substances used in pharmaceutical formulations. Such pharmaceutical preparations may be manufactured in known manner, for example, by means of mixing, granulating, tabletting, sugar-coating, or film coating processes.

25 Liquid dispersions for oral administration may be syrups, emulsions and suspensions. The syrups may contain as carriers, for example, saccharose or saccharose with glycerine and/or mannitol and/or sorbitol. Suspensions and emulsions may contain as carrier, for example a natural gum, agar, sodium alginate, pectin, methylcellulose, carboxymethylcellulose, or polyvinyl alcohol. The suspensions or solutions for 30 intramuscular injections may contain, together with the active compound, a pharmaceutically acceptable carrier, e.g. sterile water, olive oil, ethyl oleate, glycols, e.g.

propylene glycol, and if desired, a suitable amount of lidocaine hydrochloride.

Solutions for intravenous or infusions may contain as carrier, for example, sterile water or preferably they may be in the form of sterile, aqueous, isotonic saline solutions.

A therapeutically effective non-toxic amount of substance is administered. The dose 5 may be determined according to various parameters, especially according to the substance used; the age, weight and condition of the patient to be treated; the route of administration; and the required regimen. Again, a physician will be able to determine the required route of administration and dosage for any particular patient. A typical daily dose is from about 0.1 to 50 mg per kg, preferably from about 0.1mg/kg to 10mg/kg of body weight, 10 according to the activity of the specific inhibitor, the age, weight and conditions of the subject to be treated, the type and severity of the disease and the frequency and route of administration. Preferably, daily dosage levels are from 5 mg to 2 g.

Agricultural use

15 Modulators identified by the method of the invention may be administered to plants in order to prevent or treat fungal infections. The modulators are normally applied in the form of compositions together with one or more agriculturally acceptable carriers or diluents and can be applied to the crop area or plant to be treated, simultaneously or in succession with further compounds.

20 The modulators of the invention can be applied together with carriers, surfactants or application-promoting adjuvants customarily employed in the art of formulation. Suitable carriers and diluents correspond to substances ordinarily employed in formulation technology, e.g. natural or regenerated mineral substances, solvents, dispersants, wetting agents, tackifiers, binders or fertilizers.

25 A preferred method of applying the modulators of the present invention or an agrochemical composition which contains them is leaf application. The number of applications and the rate of application depend on the intensity of infection by the fungus. However, the active ingredients can also penetrate the plant through the roots via the soil (systemic action) by impregnating the locus of the plant with a liquid composition, or by 30 applying the compounds in solid form to the soil, e.g. in granular form (soil application). The active ingredients may also be applied to seeds (coating) by impregnating the seeds

either with a liquid formulation containing active ingredients, or coating them with a solid formulation. In special cases, further types of application are also possible, for example, selective treatment of the plant stems or buds.

The active ingredients are used in unmodified form or, preferably, together with the 5 adjuvants conventionally employed in the art of formulation, and are therefore formulated in known manner to emulsifiable concentrates, coatable pastes, directly sprayable or dilutable solutions, dilute emulsions, wettable powders, soluble powders, dusts, granulates, and also encapsulations, for example, in polymer substances. Like the nature of the 10 compositions, the methods of application, such as spraying, atomizing, dusting, scattering or pouring, are chosen in accordance with the intended objectives and the prevailing circumstances. Advantageous rates of application are normally from 50g to 5kg of active ingredient (a.i.) per hectare ("ha", approximately 2.471 acres), preferably from 100g to 2kg a.i./ha, most preferably from 200g to 500g a.i./ha.

The formulations, compositions or preparations containing the active ingredients and, 15 where appropriate, a solid or liquid adjuvant, are prepared in known manner, for example by homogeneously mixing and/or grinding active ingredients with extenders, for example solvents, solid carriers and, where appropriate, surface-active compounds (surfactants).

Suitable solvents include aromatic hydrocarbons, preferably the fractions having 8 to 12 carbon atoms, for example, xylene mixtures or substituted naphthalenes, phthalates such 20 as dibutyl phthalate or dioctyl phthalate, aliphatic hydrocarbons such as cyclohexane or paraffins, alcohols and glycols and their ethers and esters, such as ethanol, ethylene glycol, monomethyl or monoethyl ether, ketones such as cyclohexanone, strongly polar solvents such as N-methyl-2-pyrrolidone, dimethyl sulfoxide or dimethyl formamide, as well as epoxidized vegetable oils such as epoxidized coconut oil or soybean oil; or water.

25 The solid carriers used e.g. for dusts and dispersible powders, are normally natural mineral fillers such as calcite, talcum, kaolin, montmorillonite or attapulgite. In order to improve the physical properties it is also possible to add highly dispersed silicic acid or highly dispersed absorbent polymers. Suitable granulated adsorptive carriers are porous types, for example pumice, broken brick, sepiolite or bentonite; and suitable nonsorbent 30 carriers are materials such as calcite or sand. In addition, a great number of pregranulated materials of inorganic or organic nature can be used, e.g. especially dolomite or pulverized

plant residues.

Depending on the nature of the active ingredient to be used in the formulation, suitable surface-active compounds are nonionic, cationic and/or anionic surfactants having good emulsifying, dispersing and wetting properties. The term "surfactants" will also be understood as comprising mixtures of surfactants.

Suitable anionic surfactants can be both water-soluble soaps and water-soluble synthetic surface-active compounds. Suitable soaps are the alkali metal salts, alkaline earth metal salts or unsubstituted or substituted ammonium salts of higher fatty acids (chains of 10 to 22 carbon atoms), for example the sodium or potassium salts of oleic or stearic acid, or of natural fatty acid mixtures which can be obtained for example from coconut oil or tallow oil. The fatty acid methyltaurin salts may also be used.

More frequently, however, so-called synthetic surfactants are used, especially fatty sulfonates, fatty sulfates, sulfonated benzimidazole derivatives or alkylarylsulfonates. The fatty sulfonates or sulfates are usually in the form of alkali metal salts, alkaline earth metal salts or unsubstituted or substituted ammonium salts and have a 8 to 22 carbon alkyl radical which also includes the alkyl moiety of alkyl radicals, for example, the sodium or calcium salt of lignonsulfonic acid, of dodecylsulfate or of a mixture of fatty alcohol sulfates obtained from natural fatty acids. These compounds also comprise the salts of sulfuric acid esters and sulfonic acids of fatty alcohol/ethylene oxide adducts. The sulfonated benzimidazole derivatives preferably contain 2 sulfonic acid groups and one fatty acid radical containing 8 to 22 carbon atoms. Examples of alkylarylsulfonates are the sodium, calcium or triethanolamine salts of dodecylbenzenesulfonic acid, dibutylnaphthalenesulfonic acid, or of a naphthalenesulfonic acid/formaldehyde condensation product. Also suitable are corresponding phosphates, e.g. salts of the phosphoric acid ester of an adduct of p-nonylphenol with 4 to 14 moles of ethylene oxide.

Non-ionic surfactants are preferably polyglycol ether derivatives of aliphatic or cycloaliphatic alcohols, or saturated or unsaturated fatty acids and alkylphenols, said derivatives containing 3 to 30 glycol ether groups and 8 to 20 carbon atoms in the (aliphatic) hydrocarbon moiety and 6 to 18 carbon atoms in the alkyl moiety of the alkylphenols.

Further suitable non-ionic surfactants are the water-soluble adducts of polyethylene

oxide with polypropylene glycol, ethylenediamine propylene glycol and alkylpolypropylene glycol containing 1 to 10 carbon atoms in the alkyl chain, which adducts contain 20 to 250 ethylene glycol ether groups and 10 to 100 propylene glycol ether groups. These compounds usually contain 1 to 5 ethylene glycol units per propylene glycol unit.

Representative examples of non-ionic surfactants are nonylphenolpolyethoxyethanols, castor oil polyglycol ethers, polypropylene/polyethylene oxide adducts, tributylphenoxypolyethoxyethanol, polyethylene glycol and octylphenoxyethoxyethanol. Fatty acid esters of polyoxyethylene sorbitan and 10 polyoxyethylene sorbitan trioleate are also suitable non-ionic surfactants.

Cationic surfactants are preferably quaternary ammonium salts which have, as N-substituent, at least one C₈-C₂₂ alkyl radical and, as further substituents, lower unsubstituted or halogenated alkyl, benzyl or lower hydroxyalkyl radicals. The salts are preferably in the form of halides, methylsulfates or ethylsulfates, e.g. 15 stearyltrimethylammonium chloride or benzyl(di(2-chloroethyl)ethyl)ammonium bromide.

The surfactants customarily employed in the art of formulation are described, for example, in "McCutcheon's Detergents and Emulsifiers Annual", MC Publishing Corp. Ringwood, New Jersey, 1979, and Sisely and Wood, "Encyclopaedia of Surface Active Agents," Chemical Publishing Co., Inc. New York, 1980.

20 The agrochemical compositions usually contain from about 0.1 to about 99% preferably about 0.1 to about 95%, and most preferably from about 3 to about 90% of the active ingredient, from about 1 to about 99.9%, preferably from about 1 to 99%, and most preferably from about 5 to about 95% of a solid or liquid adjuvant, and from about 0 to about 25%, preferably about 0.1 to about 25%, and most preferably from about 0.1 to 25 about 20% of a surfactant. Whereas commercial products are preferably formulated as concentrates, the end user will normally employ dilute formulations.

All of the features described herein may be combined with any of the above aspects, in any combination.

30 Embodiments of the invention will now be described by way of example, with reference to the accompanying drawings in which:-

Figure 1 illustrates a multiple sequence alignment of amino acid sequences corresponding to fungal and bacterial 2031 and OYE family oxidoreductases;

Figure 2 illustrates a multiple sequence alignment of nucleic acid sequences corresponding to fungal 2031 and family oxidoreductases;

5 Figure 3A illustrates the expression of recombinant 2031 OR; B shows purified recombinant 2031 OR.

Figure 4. Phylogenetic tree showing relationships between *A. fumigatus* 2031 OR and similar proteins. This demonstrates a 2031 OR clade, which can be distinguished from the OYE proteins;

10 Figure 5 illustrates reduction of a range of substrates by recombinant 2031 OR.

Figure 6 illustrates the inhibition of 2031 OR by two compounds identified from a screen.

EXAMPLESExample 1. Identification of an essential gene in *Aspergillus fumigatus*

5 An essential region of the *A. fumigatus* genome was identified using the mycobank technology as described in patent WO00177295A1 with the following modifications:

Re-haplodisation (section 1.6):

P24 lines 11-18: Conidia (*A. fumigatus*) were collected from a stable diploid

10 transformant colony and approximately 3×10^4 spores were used to inoculate 1 ml of SAB broth containing 1mg/ml FPA. This culture was incubated with shaking (200 rpm) at 37°C for 20 hours. 100 μ l of the culture was spread onto complete media containing 0.2 mg/ml FPA and incubated at 37 °C for 3 days or until rapidly growing sectors emerged.

15 Conidia were collected from each sector and plated onto nitrate, nitrite and hypoxanthine media and the nitrogen utilisation profiles of the resulting conidia assessed. Colonies with the nitrogen utilisation profiles of the parental strains indicated breakdown of the diploid to a haploid. 44 haploid sectors were isolated from transformant 2031. None of the haploids isolated were hygromycin resistant indicating the insertion of the *hph* gene into a portion of the genome required for function.

20

Transformation (section 1.7):

P25 line 9: Plasmid pAN7-1 linearised with HindIII was used as the transforming vector.

PAN7-1 carries the *hph* gene which confers hygromycin resistance.

25 P25 lines 17-20: 1 ml of cold YED was added to the cuvette and incubated at 37 °C for 1 h. Aliquots were spread on selective agar (complete media with 250 μ g/ml hygromycin). Colonies growing on selective media were deemed putative transformants.

30 The point of insertion was identified using the plasmid rescue method outlined on page 31 lines 5-17. The insertion site was confirmed by employing PCR: Using the sequence obtained from plasmid rescue data a primer was designed within the sequence of pAN7-1

and a complementary primer was designed within the predicted sequence near the point of insertion. Genomic DNA isolated from the diploid 2031 was used as a template.

The resulting DNA sequence (experiment 2031, with 175 bases of upstream pAN7.1 sequence removed) corresponds to the gDNA sequence immediately downstream of the insertion site and is given as SEQ ID No. 45.

Example 2. Characterisation of the essential gene

2.1 Genome analysis

10 The TIGR *A. fumigatus* database (www.TIGR.org) was searched (blastn) with the sequence SEQ ID No. 45, identified in Example 1 above, and a match to contig 4798 (Eval 4.6e-148) was identified. The appropriate region of the contig sequence was down-loaded from www.tigr.org and gene predictions carried out using Genscan (genes.mit.edu/GENSCAN.html; Settings; organism = vertebrate; Suboptimal exon cutoff = 1.00).

15 The *ab initio* prediction of genes from genomes is known to be an inaccurate process (Burset, M. and Guigó, 1996, *Genomics*, 34, 353-367) and this is particularly so when the programs used have not been specifically trained for the genome under examination (as is the case here). It is therefore necessary to carefully examine the predictions, to compare 20 any predicted genes with any homologous proteins, and to exploit the operative's knowledge of fungal gene structure, and thus to arrive at an informed prediction. The predicted genes were therefore compared with similar sequences using blastp (<http://blast.genome.ad.jp/>), the multiple alignment program ClustalX (Thompson et al., 1997, *Nucleic Acids Research*, 24:4876-4882), and the alignment editor/ viewer Align (Hepperle, 25 D., 2001: Multicolor Sequence Alignment Editor. Institute of Freshwater Ecology and Inland Fisheries, 16775 Stechlin, Germany). Gene structures were visualised and modified using Artemis (<http://www.sanger.ac.uk/Software/Artemis/>; Rutherford et al., 2000, *Bioinformatics* 16, 944-945).

30 The gene adjacent to the insertion site corresponded to bases 299-469 (exon 1) and bases 520-1618 (exon 2) of the genomic sequence given as SEQ ID No. 1. The protein

sequence for the gene is given as SEQ ID No. 3. The insertion site was 735 bases upstream of the 5' ATG start of the gene.

Searches of the protein databases at <http://blast.genome.ad.jp/> showed that protein SEQ ID No. 3 is a member of the NADH-dependent flavin oxidoreductase family. This 5 protein is henceforth referred to as 2031 oxidoreductase (2031 OR; having come from mycobank experiment 2031). Other 2031 OR-like proteins were also identified (see Example 4.1). The NADH-dependent flavin oxidoreductase family also includes Old Yellow Enzyme (OYE), from *S. cerevisiae* and other fungi, although 2031 ORs can be distinguished from OYES.

10 Referring to Figures 1, there is shown a multiple alignment of the 2031 OR amino acid sequence from *A. fumigatus* along with related ORs from other fungi and bacteria (see also Example 4). Regions 1-11 refer to amino acids conserved between ORs.

Fungal 2031 ORs are given by: SEQ ID Nos. 3, 6 and 8, *A. fumigatus*; SEQ ID No. 10, *A. nidulans*; SEQ ID Nos. 12 and 14, *C. albicans*; SEQ ID Nos. 16 and 19, *N. crassa*; 15 SEQ ID Nos 22 and 44, *M. grisea*; SEQ ID No. 24, (NP_595868), *S. pombe*; SEQ ID No. 27, *C. trifolii*; SEQ ID Nos. 30, 33 and 35, *F. sporotrichioides*; SEQ ID Nos. 38 and 83, *F. graminearum* SEQ ID Nos. 40 and 42, *M. graminicola*; SEQ ID No. 85, *U. maydis*.

Bacterial ORs resembling 2031 are: T44612 (*Pseudomonas putida*), SEQ ID No. 86; NP_625402 (*Streptomyces coelicolor*), SEQ ID No. 87; NP_295913 (*Deinococcus radiodurans*), SEQ ID No. 88; AF320254 (*Azoarcus evansii*), SEQ ID No. 89.

Fungal ORs similar to the Old Yellow Enzyme family (originally identified in *S. cerevisiae*): *A. fumigatus*, Af4875 and Af4961, SEQ ID Nos. 90 and 91 respectively; *C. albicans*, Ca2460 and A36990, SEQ ID Nos. 92 and 93 respectively; *N. crassa*, Nc4452, SEQ ID No. 94; *S. cerevisiae*, OYE1, OYE2 and OYE3, SEQ ID Nos. 95-97 respectively.

25 Details of the sequence searches that identified the ORs other than SEQ ID No. 3, and methods for the construction of multiple alignments are given in Example 4 hereinafter.

Referring to Figure 2, there is shown a multiple alignment of the nucleotide sequence of 2031 OR from *A. fumigatus* along with related 2031 ORs from other fungi and bacteria 30 (see also Example 4). Regions 1-11 refer to amino acids conserved between 2031 ORs at the amino acid level. Fungal 2031 ORs are given by SEQ ID No.: SEQ ID Nos. 1, 2, 4, 5,

and 7, *A. fumigatus*; SEQ ID No. 9, *A. nidulans*; SEQ ID Nos. 11 and 13, *C. albicans*; SEQ ID Nos. 15, 17 and 18, *N. crassa*; SEQ ID Nos. 20, 21 and 43, *M. grisea*; SEQ ID No. 23 (NP_595868), *S. pombe*; SEQ ID Nos. 25 and 26, *C. trifolii*; SEQ ID Nos. 28, 29, 31, 32 and 34, *F. sporotrichioides*; SEQ ID Nos. 36, 37 and 82, *F. graminearum*; SEQ ID Nos. 39 and 41, *M. graminicola*; SEQ ID No. 84, *U. maydis*.

5 Details of the sequence searches that identified the ORs, and methods for the construction of multiple alignments are given in Example 4 hereinafter.

2.2 Genomic Sequencing of Genes

10 Following the above bioinformatic analyses, the genomic sequences of 2031 OR was experimentally determined.

2.2.1 Bacterial and Fungal Strains

For bacterial cloning, *E. coli* strains Top10 (Invitrogen) and select96 (Promega) were used
15 in accordance with manufacturers' instructions.

A. fumigatus clinical isolate AF293 (ref. No. NCPF7367; available to the public from the NCPF repository; Bristol, U.K.); the CBS repository (Belgium) or from Dr. David Denning's clinical isolate culture collection, Hope Hospital, Salford. U.K.) is the preferred strain according to the present invention. AF293 was isolated in 1993 from the lung biopsy
20 of a patient with invasive aspergillosis and aplastic anaemia. It was donated by Shrewsbury PHLS.

*2.2.2 Purification of *A. fumigatus* genomic DNA*

To obtain mycelial material for genomic DNA isolation, approximately 10^7 *A. fumigatus* conidia were inoculated in 50 ml of Vogel's minimal medium and incubated with shaking at 200 rpm until late exponential phase (18-24 h) at 37°C. Mycelium was dried down onto Whatmann 54 paper using a Buckner funnel and a side-arm flask attached to a vacuum pump and washed with PBS/Tween. At this point, the mycelium could be freeze-dried for extraction at a later date.

30 The mycelium (fresh or freeze dried) was ground to a powder using liquid nitrogen in a -20°C cooled mortar. The ground biomass was transferred to 50 ml tubes on ice up to

the 10 ml mark. An equal volume of extraction buffer (0.7 M NaCl; 0.1 M Na₂SO₃; 0.1 M Tris-HCl pH 7.5; 0.05 M EDTA; 1% (w/v) SDS; pre-warmed to 65°C) was then added to each tube, mixed thoroughly with a pipette tip and incubated at 65°C for 20 minutes in a water bath. A volume of chloroform/isoamyl alcohol (24:1) equivalent to the volume of the 5 original biomass was then added to each tube, tubes were mixed thoroughly and incubated on ice for 30 min. Tubes were then centrifuged at 3,500 x g for 30 min and the aqueous phase carefully transferred to fresh 50 ml tubes without disturbing the interface.

An equal volume of chloroform/isoamyl alcohol (24:1) was added, the tubes 10 vortexed and incubated on ice for 15 minutes. Tubes were then spun at 3,500 x g for 15 minutes. After this spin, if large amounts of precipitate were still present, the supernatant was removed and the chloroform:isoamyl alcohol step repeated. The supernatant was removed and placed in clean sterile Oak Ridge tubes. An equal volume of isopropanol was 15 added and mixed gently. Tubes were incubated at room temperature for at least 15 minutes. Tubes were then centrifuged at 3,030 x g for 10 minutes at 4°C to pellet the DNA. The supernatant was removed and the pellet allowed to air dry for 10-25 minutes. The pellet 20 was suspended in 2 ml sterile water. 1 ml of 7.5 M ammonium acetate was added, mixed and incubated on ice for 1 hour. Tubes were centrifuged at 12,000 x g for 30 min, the supernatants transferred to a fresh tube and 0.54 volumes of isopropanol were added, mixed and incubated at room temperature for at least 15 minutes. Tubes were then centrifuged at 5,930 x g for 10 min, the supernatant was removed and the pellet washed in 1 ml of 70% ethanol. Tubes were centrifuged at 5,930 x g for 10 min and all the ethanol 25 was removed. The pellet was air dried for 20-30 minutes at room temperature and suspended in 0.5-1.0 ml of TE (10 mM Tris-HCl pH 7.5; 1mM EDTA) Finally, the DNA was treated with RNase A (5 µl of 1mg/ml stock).

25

2.2.3 PCR Reactions

Primers were designed to the upstream and downstream regions of the *A. fumigatus* AF293 2031 OR; cloning primer pair SEQ ID Nos. 46 (Ox9_for) and 47 (Ox10_rev). The following reagents and conditions were used:

30

PCR Master Mix

10x high fidelity PCR buffer	5 µl
dNTP (clontech: 10mM)	1 µl
nH ₂ O	39 µl
5 Pfu Ultra Polymerase (2.5U/µl)	1 µl
Forward primer (Ox9_for: 10 pmol/µl stock)	1 µl
Reverse primer (Ox10_rev: 10 pmol/µl stock)	1 µl
gDNA (1:30 dilution of stock)	2 µl

10 PCR Cycle

- 1) 95° C 2 min
- 2) 95° C 30 sec
- 3) 54° C 30 sec
- 4) 72° C 2 min
- 15 5) 72° C 10 min
- 6) 8° C Hold

20 40 cycles of steps 2-4 were carried out and the PCR products were run on a gel. The product band (1.9kb) was excised from the gel and purified using Qiagen's QIAquick Gel Extraction Kit (Qiagen Ltd, Boundary Court, Gatwick Road, Crawley, West Sussex, RH10 9AX, UK) according to the manufacturers instructions and eluted into 30 µl of sterile water (BDH molecular biology grade/filter sterile).

2.2.4 Genomic DNA Cloning and Sequencing

25 Since the gDNA was amplified using Pfu ultra polymerase which produces blunt ends it was necessary to add 'A' overhangs before ligating in to pGEM Teasy. 12.5 µl of purified PCR product was incubated with 12.5 µl 2x PCR Reddy Mix (ABGene) at 70° C for 30 minutes. The sample was then purified using Qigen Qiaquick gel extraction kit and eluted in 30 µl of molecular biology grade water.

30 The PCR product was then ligated into pGEM-Teasy (Promega) using the following ligation mixture:

2x Buffer	5 μ l
pGEM Teasy	1 μ l
PCR product	3 μ l
5 T4 DNA Ligase	1 μ l

The reaction was incubated over-night at 4° C.

2 μ l of the ligation mix were then added to Select 96 cells (Promega) and incubated for 20 min on ice. Cells were then heat shocked at 42° C for 45 secs and placed 10 back on ice. 250 μ l of room temp. SOC medium was then added and the cells incubated for 1 hour at 37° C, with shaking at 220 rpm. 50 and 200 μ l amounts were then plated on to LB agar plates containing ampicillin (100 μ g/ml), 50 μ l X-gal (4%) and 10 μ l IPTG (100 mM) and incubated over night at 37° C.

Individual white colonies were picked from each transformation inoculated into LB 15 with ampicillin (100 μ g/ml) and incubated over-night at 37° C, with shaking at 220 rpm. Plasmid DNA was extracted using Qiagen miniprep kit according to the manufacturers instructions. 1 μ l of plasmid DNA was digested with EcoRI for 1 hour at 37° C. Fragment sizes were calculated to be 3Kb and 1.6Kb for gDNA and 3Kb and 1.2 Kb for cDNA. Clones showing the correct restriction digest pattern were sequenced at MWG Biotech UK 20 Ltd, Waterside House, Peartree Bridge, Milton Keynes, MK6 3BY. The experimentally determined sequence of 2031 OR was identical in the coding regions to that identified by bioinformatic analyses (Example 2).

Example 3. cDNA sequencing and RACE for 2031 OR

25 The internal sequence of the 2031 OR message was experimentally determined by cloning and sequencing cDNA, and the 5' and 3' ends of the gene were determined by RACE (Rapid Amplification of cDNA Ends).

30 3.1 cDNA cloning and sequencing

3.1.1 Preparation of *A. fumigatus* RNA and cDNA

Fungal cultures were prepared as described in Example 2.2.2. Cultures were harvested by filtration, then washed twice with DEPC-treated water and transferred to a 50ml Falcon tube. Samples were frozen in liquid nitrogen and stored at -80°C until required.

To prepare RNA, fungal samples were ground to a fine powder under liquid nitrogen. 5 RNA was then extracted using the Qiagen RNeasy Plant Mini Kit following the protocol for isolation of total RNA from filamentous fungi in the RNeasy Mini Handbook (06/2001, Pages 75-78, http://www.qiagen.com/literature/handbooks/rna/rnamini/1016272HBRNY_062001WW.pdf). The following modifications were used: At step 3, RLC was used as the lysis buffer of choice; At step 7, the Rneasy 10 column was incubated for 5 min at room temperature after addition of RW1; The optional step 9a was carried out; At step 10, 30µl RNase-free water was added, the samples incubated for 10 min at room temperature, and then centrifuged; At step 11, the elution step was repeated to give a total volume of 60 µl RNA.

15 DNA contamination was removed from the RNA by the addition of Dnase, using 2 µl DNase per µg RNA, in the presence of 10X DNase buffer and incubating at 37°C for 2h. DNase-treated RNA was cleaned up using the RNeasy Plant Mini Kit following the RNeasy Mini Protocol for RNA Cleanup (RNeasy Mini Handbook 06/2001, pages 79-81).

To synthesise cDNA from the above RNA the following reaction mixture was prepared: 100ng-1µg of DNA-free RNA, 3µl oligo (dT) (100 ng/µl), and DEPC-treated 20 water to a total volume of 42 µl. Samples were incubated in a heat block at 65°C for 5 min after which they were allowed to cool slowly to room temperature. Then 2µl Ultrapure dNTPs, 1µl reverse transcriptase (Stratascript) and 5µl 10X reverse transcriptase reaction buffer (Stratascript) were added. Samples were incubated at 42°C for 1h, denatured at 90°C for 5 min and then cooled on ice.

25

3.1.2 Production of cDNA constructs

PCR was carried out using the cDNA above to generate cDNA fragments using the primer pair SEQ ID No. 48 (Ox1_for) and SEQ ID No. 49 (Ox3_rev). PCR reactions were carried out using the following reagents and conditions:

30

PCR Master Mix

10x high fidelity PCR buffer	5 μ l
dNTP (clontech: 10mM)	1 μ l
MgSO ₄ (50 mM)	2 μ l
5 nH ₂ O	37.8 μ l
Platinum TAQ Polymerase (5U/ μ l)	0.2 μ l
Forward primer (Ox1_for: 10 pmol/ μ l stock)	1 μ l
Reverse primer (Ox3_rev: 10 pmol/ μ l stock)	1 μ l
cDNA	2 μ l

10

PCR Cycle

- 1) 94° C 5 min
- 2) 94° C 30 sec
- 3) 53° C 30 sec
- 15 4) 68° C 90 sec
- 5) 68° C 10 min
- 6) 8° C Pause

20 Cycles 2-4 were run 40 times in total. The amplicon was 1269 bp. The PCR products were purified using Qiagen's QIAquick PCR Purification Kit (Qiagen Ltd, Boundary Court, Gatwick Road, Crawley, West Sussex, RH10 9AX, UK) according to the manufacturers instructions. The purified PCR products were examined on agarose gels.

25 PCR products were ligated into pGEM-Teasy, used to transform Select 96 cells, and sequenced as described in 2.2.4 above. The cDNA sequence obtained is given as bases 115 – 1385 of SEQ ID No. 2.

3.2 RACE

30 To determine the 5' and 3' ends of the genes, RACE (Rapid Amplification of cDNA Ends) was carried out, using the GeneRacer™ Kit (Invitrogen; cat. No. L1502-01), essentially as per manufacturers instructions.

3.2.1 Preparation of RNA

A. fumigatus biomass was prepared as described in 2.2.2. RNA was prepared using the FastRNA kit (QBIogene) following the manufacturer's instructions (Revision 6030-999-1J05) with the following amendments: At step 1 40 mg of biomass was used per 5 extraction; At step 2, samples were processed for 20 seconds at speed 5, incubated on ice for 3 minutes, and processed again for 20 seconds at speed 5; At step 3 samples were centrifuged for 5 minutes; At step 5, 500 µl DIPS were added, mixed, and incubated at room temperature for 2 minutes. Samples were mixed again and incubated for a further 2 minutes; At step 6 two washes in 250 µl SEWS were carried out; At step 7, the pellet was 10 dissolved in 50 µl SAFE buffer.

3.2.2 RACE

1 µg total RNA prepared as described above was de-phosphorylated in a 10 µl reaction using 10 units of calf intestinal phosphate (CIP), 1 µl 10X CIP buffer and 40U 15 RNaseOut™ (made up to 10 µl in DEPC water) at 50°C for 1 hour. Samples were then made up to 100 µl with DEPC water and the RNA extracted with 100 µl (25:24:1) phenol:chloroform: isoamyl alcohol. RNA was then precipitated by the addition of 2 µl mussel glycogen (10mg/ml), 10 µl 3M sodium acetate, pH 5.2 and 220 µl 95% ethanol and the sample frozen on dry ice for 10 minutes. RNA was pelleted by centrifugation at 14,500 20 rpm for 20 minutes at 4°C, washed with 70% ethanol, air dried and re-suspended in 8 µl DEPC water.

De-phosphorylated RNA (7 µl) was de-capped in a 10 µl reaction with 0.5 U tobacco acid pyrophosphatase (TAP), 1 µl 10x TAP buffer and 40U RnaseOut™ for 1 hour at 25 37°C. RNA was extracted with phenol:chloroform and precipitated as above, and then re-suspended in 7 µl DEPC-treated water.

De-phosphorylated, de-capped RNA (7 µl) was added to the pre-aliquoted GeneRacer™ RNA Oligo (0.25 µg) and incubated at 65°C for 5 minutes. A 10 µl ligation reaction was then set up by the addition of 1 µl 10x ligase buffer, 1 µl 10mM ATP, 40U 30 RnaseOut™ and 5U T4 RNA ligase and incubated at 37°C for 1 hour. RNA was extracted and precipitated as described previously and re-suspended in 11 µl DEPC-treated water.

First-strand cDNA was prepared by the addition of 1 μ l GeneRacerTM Oligo dT primer and 1 μ l dNTP mix (10mM each) to 10 μ l ligated RNA and incubated at 65°C for 5 minutes. The following reagents were added to the 12 μ l ligated RNA and primer mix; 4 μ l 5x first strand buffer, 2 μ l 0.1M DTT, 1 μ l RNaseOutTM and 1 μ l SuperScriptTM II RT (200U/ μ l) and incubated first at 42°C for 50 minutes and then, to stop the reaction, at 70°C for 15 minutes. 2U RNase H was added to the reaction mix and incubated at 37°C for 20 minutes.

To amplify the 5'cDNA ends a 50 μ l PCR reaction was set up using 1 μ l of the RACE-ready cDNA prepared above, 1 μ l GeneRacerTM 5' primer, 1 μ l reverse gene-specific primer (SEQ ID No. 50; Ox6race_rev: 5 pmol/ μ l stock), 1 μ l dNTP solution (10mM each), 2 μ l 50 mM MgSO₄, 5 μ l High Fidelity PCR buffer, 0.5 μ l Platinum[®] *Taq* DNA Polymerase High Fidelity (5 U/ μ l) and 38.5 μ l sterile water. Cycling parameters are given in Table II below.

A second, nested PCR stage was then set up using 1 μ l of the RACE cDNA from the first stage above, 1 μ l Nested 5' primer (supplied with kit), 1 μ l reverse gene-specific primer (SEQ ID No. 50; Ox6race_rev: 5 pmol/ μ l stock), 1 μ l dNTP solution (10 mM each), 2 μ l 50 mM MgSO₄, 5 μ l High Fidelity PCR buffer, 0.5 μ l Platinum[®] *Taq* DNA Polymerase High Fidelity (5 U/ μ l) and 38.5 μ l sterile water. Cycling parameters are given in Table II below.

To amplify 3' ends a 50 μ l PCR reaction was set up using 1 μ l of the RACE-ready cDNA prepared above, 1 μ l GeneRacerTM 3' primer (10 μ M), 1 μ l forward gene-specific primer (SEQ ID No. 51; Ox7race_for: 5 pmol/ μ l stock), 1 μ l dNTP solution (10 mM each), 2 μ l 50 mM MgSO₄, 5 μ l High Fidelity PCR buffer, 0.5 μ l Platinum[®] *Taq* DNA Polymerase High Fidelity (5 U/ μ l) and 38.5 μ l sterile water. Cycling parameters are given in Table II below:

A second, nested PCR stage was then set up using 1 μ l of the 3' RACE cDNA from the first stage above, 1 μ l Nested 3' primer (supplied with kit), 1 μ l reverse gene-specific primer (SEQ ID No. 52; Ox8race_for: 5 pmol/ μ l stock), 1 μ l dNTP solution (10mM each), 2 μ l 50 mM MgSO₄, 5 μ l High Fidelity PCR buffer, 0.5 μ l Platinum[®] *Taq* DNA

Polymerase High Fidelity (5U/μl) and 38.5 μl sterile water. Cycling parameters are given in Table II below.

Table II: Cycling parameters for 5' and 3'RACE

5' and 3' RACE			Nested PCR		
94 °C	2min	1 cycle	94° C	2 min	1 cycle
94 °C	30s	5 cycles	94° C	30 sec	25 cycles
72 °C	1min		67° C	30 sec	
			68° C	1 min	
94 °C	30s	5 cycles			
70 °C	1min		68° C	10 min	1 cycle
94 °C	30s	25 cycles	8° C	Hold	
64 °C	30s				
68 °C	1min				
68 °C	10min	1 cycle			
8 °C	Hold				

5

5' and 3' RACE confirmed the predicted 5' ATG and 3' stop codon as well as giving the 5' and 3' untranslated regions shown as bases 1-114 and 1385 – 1921 of SEQ ID No. 2. The coding sequence for 2031 OR thus determined was identical to that given as bases 299-469 and 520-1618 of the gDNA given as SEQ ID No. 1.

10

Example 4. Identification of other fungal 2031 ORs and related genes

Homologs of *A. fumigatus* 2031 OR were identified in other fungi and bacteria by means of bioinformatics analysis. Sequences identified by bioinformatics can be used to design

primers which in turn can be used in PCR to generate DNA coding for the 2031 OR homolog.

Alternatively, degenerate PCR can be used to obtain sequence for novel genes, which can then be used to generate probes for screening cDNA or genomic libraries of the 5 organism of interest to identify clones containing the 2031 OR homolog. As a further alternative, Southern blots using fragments of genes from one species as probes can be used to identify the presence of a homolog in the genome of a second species. The same probe can then be used to screen cDNA or genomic DNA libraries. Once clones corresponding to the novel genes have been identified they can be expressed for functional 10 characterisation of the protein.

4.1 Identification of homologs by bioinformatics

Analysis of the 2031 OR protein sequence with PFAM (http://www.sanger.ac.uk/Software/Pfam/) identified this as a member of the Oxidored 15 FMN family (PF00724), E-value 3.6e-57. This includes the well-characterised “Old Yellow Enzyme” proteins of *S. cerevisiae* and other fungi.

Homologs of *A. fumigatus* 2031 OR sequence were identified by database searches (see Table III). Where necessary, matching contigs were down-loaded and genes predicted from genomic DNA by Genscan analysis, blast searches, alignment and visualisation with 20 Artemis as described in Example 2. Protein and nucleotide multiple alignments were generated for 2031 OR and related genes (Figures 1 and 2).

Protein and nucleic acid multiple alignments are generated by means of programs such as ClustalX (Thompson et al., 1994, Nucleic Acids Research, 22, 4673-4680; 25 Thompson et al., 1997, Nucleic Acids Research, 24, 4876-4882;) and/or using manual alignment editors such as Align (Hepperle, D., 2001: Multicolor Sequence Alignment Editor. Institute of Freshwater Ecology and Inland Fisheries, 16775 Stechlin, Germany).

Table III: 2031 homologs identified by database searches

Contig/EST/ predicted gene	E- value ¹	SEQ ID No.			Species (details of search given in footnotes)
		EST/gDNA	CDNA ²	Protein	
4929	6.6e-81	4	5	6	<i>Aspergillus fumigatus</i> ³
4951	1.1e-68	7	-	8	<i>Aspergillus fumigatus</i> ³
4875	5.7e-13	-	-	-	<i>Aspergillus fumigatus</i> ³
4961	3.2e-10	-	-	-	<i>Aspergillus fumigatus</i> ³
1.112	3e-33	9	-	10	<i>Aspergillus nidulans</i> ⁴
6-2431	2.6e-77	11	-	12	<i>Candida albicans</i> ⁵
6-2464	5.9e-50	13	-	14	<i>Candida albicans</i> ⁵
6-2460	5.8e-19	-	-	-	<i>Candida albicans</i> ⁵
A36990	1e-15	-	-	-	<i>Candida albicans</i> ⁶
NCU07452.1	7e-94	15	-	16	<i>Neurospora crassa</i> ⁷
NCU08900.1	2e-19	17	18	19	<i>Neurospora crassa</i> ⁷
NCU04452.1	2e-23	-	-	-	<i>Neurospora crassa</i> ⁷
MG04569.3	1e-106	20	21	22	<i>Magnaporthe grisea</i> ⁸
MG03823.3	8e-19	43	-	44	<i>Magnaporthe grisea</i> ⁸
NP_595868	1e-05	23	-	24	<i>Schizosaccharomyces pombe</i> ⁶
OYE1	1e-15	-	-	-	<i>Saccharomyces cerevisiae</i> ⁶
OYE2	4.5e-19	-	-	-	<i>Saccharomyces cerevisiae</i> ⁹
OYE3	1.0e-16	-	-	-	<i>Saccharomyces cerevisiae</i> ⁹
FsCon[0063] (EST contig)	1e-82	28	29	30	<i>Fusarium sporotrichioides</i> ¹⁰
Gz15771741	5e-76	36	37	38	<i>Fusarium graminearum</i> ¹⁰ 0
Mg[0281] (EST contig)	2e-67	39		40	<i>Mycosphaerella graminicola</i> ¹⁰

CtCon[0249] (EST contig)	1e-55	25	26	27	<i>Colletotrichium trifolii</i> ¹⁰
FsCon[0458] (EST contig)	1e-42	34		35	<i>Fusarium sporotrichioides</i> ¹⁰
FsCon[0237] (EST contig)	1e-40	31	32	33	<i>Fusarium sporotrichioides</i> ¹⁰
Mga0328f	3e-35	41		42	<i>Mycosphaerella graminicola</i> ¹⁰
T44612	1e-52	-	-	-	<i>Pseudomonas putida</i> ¹¹
NP_625402	1e-79	-	-	-	<i>Streptomyces coelicolor</i> ¹¹
NP_295913	1e-78	-	-	-	<i>Deinococcus radiodurans</i> ¹¹
AF320254	5e-55	-	-	-	<i>Deinococcus radiodurans</i> ¹¹
FG00074.1		82	82	83	<i>Fusarium graminearum</i> ¹²
Contig 1.2	1e-71	84	84	85	<i>Ustilago maydis</i> ¹³

¹E-values for blast scores refer to searches with 2031 OR protein unless specified otherwise in footnotes.

2A cDNA was generated in cases where either the gene contains multiple exons, or there
5 are probable frame-shift errors from sequencing of the EST, or the EST given is the non-coding strand.

³Search of the *A. fumigatus* genome at <http://www.TIGR.org> (tblastn) with NP_595868.

⁴Search of *A. nidulans* genome held on local machine (tblastn).

5 ⁵Search of the *C. albicans* genome at <http://www-sequence.stanford.edu/group/candida/>
10 (blastp).

⁶Search of the non-redundant protein sequence database (nr) at <http://blast.genome.ad.jp> (blastp).

⁷Search of the *N. crassa* predicted proteins at <http://www.broad.mit.edu/annotation/fungi/neurospora/> (blastp).

15 ⁸Search of the *M. grisea* predicted proteins at <http://www.broad.mit.edu/annotation/fungi/magnaporthe/> (blastp).

⁹Search of *S. cerevisiae* orf proteins (<http://mips.gsf.de/cgi->

bin/blast/blast_page?genus=yeast)

¹⁰Search of COGEME pathogenic fungal EST database at <http://cogeme.ex.ac.uk/blast.html> (tblastn, max E-val=0.1).

¹¹Search of NCBI non-redundant protein database on local machine with SEQ ID No. 1

5 (blastx). Only a selected set of hits against bacterial proteins are shown.

¹²Search of *F. graminearum* predicted proteins held on local machine (blastp).

¹³Search of *U. maydis* contigs held on local machine (tblastn).

To clarify the relationships between the 2031 OR, OYE and the hits identified from blast 10 searches, phylogenetic analysis was carried out. The PHYLIP suite of programs was used (Felsenstein, Felsenstein, J., 2002. PHYLIP (Phylogeny Inference Package) version 3.6a3. Distributed by the author. Department of Genome Sciences, University of Washington, Seattle). The multiple alignment used for the analyses was essentially that given in Figure 1 with partial sequences, gapped regions and unreliably aligned sections excluded. A 15 distance matrix was generated using PROTDIST with the Jones-Taylor-Thornton model and the tree inferred using FITCH with global rearrangements and 10 jumbles of input order. 100 bootstrap replicates were generated using SEQBOOT, distance matrices generated using PROTDIST as above, trees inferred using NEIGHBOUR, and then bootstrap values and the consensus tree were calculated using CONSENSE. Trees were 20 viewed using TREEVIEW (Page, 1996 Page, R. D. M., 1996. TREEVIEW: An application to display phylogenetic trees on personal computers. *Computer Applications in the Biosciences* 12, 357-358.)

Phylogenetic analysis identified a clade supported by good bootstrap values, which 25 included *A. fumigatus* 2031 OR and other enzymes. This could be distinguished from a clade containing OYE enzymes which was also supported by good bootstrap values. Bacterial homologs of both 2031 OR and OYE (not shown) were also identified. We have therefore identified a set of 2031 OR homologs which, surprisingly, is distinct from the well-characterised OYE family, and which, by virtue of the essentiality demonstrated for *A. fumigatus* 2031 OR, represents a set of potential targets for anti-fungal drugs

4.2 Identification of homologs by degenerate PCR

4.2.1. Preparation of genomic DNA from organism of interest

Fungal cultures are prepared using methods suitable for particular species. For example, Aspergillus and Candida species, *Cryptococcus neoformans*, *Fusarium solani* and *Trichophyton* species are maintained on Sabouraud dextrose agar at 30-35°C; *Leptosphaeria nodorum* on Malt agar medium (30 g/L malt extract; 15 g/L Bacto-agar, pH 5.5), 24.0°C; *Magnaporthe grisea* on Oatmeal agar (6.7 g/L agar, 53.3 g/L instant oatmeal) 5 25.0°C, or Cornmeal agar (Difco 0386), 26.0 C; *Phytophthora capsici* cultures were maintained on V-8 agar at 24°C; *Pyricularia oryzae* cultures were maintained on rice polish agar at 24°C under white fluorescent lights (12hr artificial day), and were subcultured every 7 - 14 days by the transfer of mycelial plugs to fresh plates; *Pythium ultimum* cultures were maintained on PDA at 24°C, and subcultured every 7 days by the transfer of aerial mycelium to fresh plates with an inoculating needle; *Rhizoctonia solani* cultures were maintained on PDA at 24°C under fluorescent lights (12 h artificial day), and 10 15 subcultured every 7 days by the transfer of mycelial plugs to fresh plates; *Ustilago maydis* cultures were maintained on PDY agar at 30°C in the dark, and subcultured by re-streaking.

Genomic DNA was prepared from cultures using standard methodologies, e.g. using the Qiagen DNeasy Plant Kit, or using methods described in Example 2.2.

20

4.2.2 PCR

Primers (SEQ ID Nos. 53 and 54) were designed on the 2031 OR-specific regions given as regions 2 and 6 in Figure 2. However, those skilled in the art will appreciate that it may be necessary to try alternative primers. PCR reactions using the above primer pair are set up 25 as follows:

12.5 µl 2x ReddyMix PCR mastermix (ABgene)

1 µl primer SEQ ID No. 53 (5 pmol)

1 µl primer SEQ ID No. 54 (5 pmol)

30 template gDNA (1.5-4 µg/ml)

nuclease-free water to give a final volume of 25 µl

The reactions are run using the following conditions on a Biometra personal PCR cycler (Thistle Scientific Ltd, DFDS House, Goldie Road, Uddington, Glasgow, G71 6NZ):-

5	Step1	95°C	5min
	Step2	95°C	1min
	Step3	53°C	1min 30sec
	Step4	68°C	2min 30sec
	Step5	72°C	10min
10	Step6	4°C	Hold

30 cycles of steps 2-4 are carried out. The PCR products are purified (to remove residual enzymes and nucleotides) using Qiagen's QIAquick PCR Purification Kit (Qiagen Ltd, Boundary Court, Gatwick Road, Crawley, West Sussex, RH10 9AX, UK) according to the manufacturers instructions and eluted into 40µl of sterile water (BDH molecular biology grade/filter sterile). The purified PCR products are examined on 1% agarose gels.

Those skilled in the art will appreciate that degenerate PCR may require variations in a number of parameters in the attempts to generate a product. These include primer concentration, template concentration, concentration of Mg²⁺ ions, elongation and annealing times, and annealing temperature. Variations in temperature can be accommodated by the use of a gradient PCR machine.

The purified PCR products are cloned into pPEM-Teasy (Promega) and then transformed into XL10-Gold® Kan ultracompetent *E. coli* cells according to the manufacturer's instructions. The transformation reactions are then plated onto LB agar plates containing ampicillin (100 µg/ml), 50 µl X-gal (4%) and 10 µl IPTG (100 mM). Following overnight incubation at 37°C, individual white colonies from each transformation are sub-cultured into LB broth containing ampicillin (100 µg/ml). After overnight incubation at 37°C with shaking, plasmids are extracted using Qiagen spin mini plasmid extraction kits according to the manufacturers instructions and sent away for full-length sequencing.

4.3 Identification of homologs by Southern Blotting

4.3.1 Digestion of genomic DNA and transfer to nylon membranes

Genomic DNA from the fungi of interest are digested with the appropriate restriction enzyme and run on 0.8 % agarose gel. The gel is then submerged in 250 mM HCl for no more than 10 mins, with shaking, at room temperature, after which the gel is rinsed with sterilised RO water.

Transfer of the DNA onto nylon membrane is carried out using 0.4 M NaOH. Transfer protocols and apparatus are well known and are described in e.g. Sambrook et al., (1989), Molecular Cloning, 2nd Edition., Cold Spring Harbor Laboratory Press. After transfer, the DNA is fixed to the membrane by baking at 120°C for 30 min. The membrane can then be used immediately, or stored dry for future use.

4.3.2. Preparation of probe

Probes are generated either by restriction digests of DNA or by PCR of an appropriate region. A suitable probe can be generated by PCR using the primer pair SEQ ID Nos. 53 and 54, *A. fumigatus* genomic DNA, and the methods give in 4.2.2.

1 µg DNA template is diluted in molecular biology water to a total volume of 16 µl, denatured in a boiling water bath for 10 mins, and quickly chilled on ice. 4 µl DIG-High Prime (1 mM dATP, 1mM dCTP, 1mM dGTP, 0.65 mM dTTP, 0.35 mM alkali-labile-digoxygenin-11-dUTP, 1 U/µl labelling grade Klenow enzyme, 5 x reaction buffer, in 50% (v/v) glycerol) is then added and the reaction incubated at 37°C for 20 hours, after which 2 µl of 200 mM EDTA pH 8.0 is added to terminate the labelling reaction. The labelling efficiency is estimated by comparison with DIG-labelled control DNA.

4.3.3. Prehybridisation and Hybridisation

The membrane is placed in a hybridisation tube containing 20 ml of prehybridisation solution (DIG Easy Hyb, Roche) per 100cm² of membrane surface area and prehybridised at 42°C for 2 hours in a hybridisation oven. The DIG- labelled probe is denatured by heating in a boiling water bath for 10 min and then chilled directly on ice. The probe is then diluted to ~200 ng/mL in hybridisation solution (Easy Hyb, Roche; at least 5 mL of

hybridisation solution is required per hybridisation). The prehybridisation solution is discarded from the hybridization tube and the hybridisation solution containing the DIG-labelled probe added quickly. The hybridisation then proceeds overnight at a 42°C in the hybridisation oven. The optimum temperature is dependant on probe size and homology with target sequence and was determined empirically.

After hybridisation, the membrane is washed twice at 42°C, 5 mins per wash, with 50 mL of stringency wash solution (3 x SSC, 0.1% SDS; where 20 x SSC buffer is 3 M NaCL, 300mM sodium citrate, pH 7.0), followed by two washes at RT, 15 min per wash, in 50 mL stringency wash solution. The stringency of these washes can be decreased by increasing the SSC concentration to 6 x SSC, 0.1% SDS and/or decreasing the wash temperatures.

4.3.4. *Detection*

The membrane is washed in 20 mL washing buffer (100mM Maleic acid, 150 mM NaCl; pH 7.5; 0.3% v/v Tween 20), and then incubated successively with the following; 20 mL blocking solution (1 % w/v blocking reagent for nucleic acid hybridisation, Roche, dissolved in 100mM maleic acid, 150 mM NaCl, pH 7), for 30 min at room temperature; Anti-DIG-alkaline phosphatase (Roche) diluted 1:5,000 in blocking buffer, 30 min at room temperature; Washing buffer, two washes each of 15 min at room temperature; Detection buffer (100 mM Tris-HCl, 100 mM NaCl; pH 9.5), 2 min at room temperature. The membrane is then removed, placed on top of an acetate sheet, and ~ 0.5 ml (per 100cm²) of CSPD or CDP-star added to the top of the membrane. A second sheet of acetate is then placed over the surface of the membrane, the assembly incubated for 5 min at room temperature and then sealed in a plastic bag. The assembly is then exposed to X-ray film for between 15 min and 1 hour. Optimal exposure time is determined empirically by increasing exposure time up to 24 hours.

The presence of a band on the gel is evidence of a gene in the genomic DNA of interest. The molecular weight of the band depends on the size of the restriction fragment that contains the gene.

Example 5. Expression during infection of wax moth larvae (*Galleria melonella*) and mice with *A. fumigatus*

5.1 Preparation of cDNA from infected wax-moth larvae

5 Wax moth larvae have been shown to be good model systems in which to study *Candida* infection (Cotter et al., 2000, FEMS Immunol Med Microbiol 27, 163-9; Brennan et al., 2002, FEMS Immunol Med Microbiol 34, 153-7). We have found that this insect system is also a good system in which to study *Aspergillus* infection (D. Law and J. Rooke, manuscript in preparation).

10

5.1.1 Growth and infection of wax-moth larvae

Spores of *A. fumigatus* (AF293), grown on Sabaraud Dextrose agar, were harvested and re-suspended in PBS/Tween 80. Spores were washed and the concentration adjusted such that a 10 µl inoculum will cause death in 90% of the test group 3-4 days after infection (for 15 AF293 this is 5.0-7.0x10⁸ cfu/ml). Inoculum concentration was estimated using an improved Neubauer haemocytometer counting chamber and confirmed by TVC enumeration.

Wax moth larvae were purchased from Livefood UK, Somerset, UK (www.livefood.co.uk), and were maintained in the dark at room temperature in wood 20 shavings prior to infection. Healthy larvae (250 mg +/- 50 mg) were selected and incubated at 4°C for 10 minutes immediately prior to infection to immobilise them. Larvae were then injected through the cuticle of the left last pro-leg with 10 µl spore suspension (100x stock), using a sterile Hamilton syringe. Larvae were then transferred to a sterile Petri dish. The following controls were also established: Larvae injected with 10 µl PBS/Tween only; 25 larvae injected with 10 µl heat killed spores (killed by incubation for 20 min 100°C); larvae pierced but not injected; and untouched larvae. Larvae were incubated at 30°C and monitored at least twice daily. All treatments and controls were carried out on batches of 10 larvae. Larval deaths and general health condition was recorded every 24 hrs and dead or moribund larvae were removed from the test group.

30

*5.1.2 Preparation of DNA-free RNA from *Aspergillus fumigatus*-infected wax moth larvae (*Galleria melonella*).*

cDNA was prepared from the following sources: Uninfected larvae; larvae after 48h infection with *A. fumigatus* (early infection); larvae after 72h infection with *A. fumigatus* (late infection); larvae infected with heat-killed *A. fumigatus* spores; and *A. fumigatus* grown in Sabaraud Dextrose agar broth for 16hr.

Frozen larvae were ground to a fine powder under liquid nitrogen in a mortar and pestle previously baked at 22°C overnight, treated with RNaseZAP, rinsed with DEPC-treated water (0.1% (v/v) DEPC, stirred for 1h and autoclaved for 1h) and cooled with liquid nitrogen. Ground sample was transferred to Eppendorf tubes (no more than 50 mg per tube) and total RNA extracted using the Qiagen RNeasy Plant Mini Kit following the protocol for isolation of total RNA from filamentous fungi in the RNeasy Mini Handbook (06/2001, Pages 75-78, http://www.qiagen.com/literature/handbooks/rna/rnamini/1016272HBRNY_062001WW.pdf).

The following modifications were used: At step 3, 600 µl RLT was added to each 50 mg tissue and vortexed; At step 4, samples were centrifuged for 3 min at maximum speed; At step 6, all samples from the same tissues were applied to the same RNeasy column; At step 7, RNeasy column was incubated for 5 min at room temperature after addition of RW1; Optional step 9a was carried out twice; At step 10, 30 µl RNase-free water was added, samples incubated for 10 min at room temperature, and then centrifuged for 1 min at 14,000 RPM; At step 11, the elution step was repeated to give a total volume of 60 µl RNA. A sample of the RNA was run on a 1.5% agarose gel and the amount of RNA quantified using the molecular marker. RNA was then stored at -80°C.

A portion of the RNA was Dnase treated using 2 µl RNase-free DNase (Promega) per µg RNA, in the presence of 10X DNase buffer (Promega) at 37°C for 4h. The RNA was then cleaned up using the Qiagen RNeasy Plant Mini Kit following the RNeasy Mini Protocol for RNA Cleanup (RNeasy Mini Handbook 06/2001, pages 79-81), but including a further DNase treatment step during clean-up as in the Rneasy handbook.

The following modifications were made: Optional step 5a was carried out; At step 6, 30µl RNase-free water was added, samples incubated for 10 min at room temperature and then centrifuged for 1 min at 14,000 RPM; At step 7, the eluate from step 6 was transferred

onto the RNeasy column, incubated for 10 min at room temperature, and then centrifuged for 1 min at 14,000 RPM. A sample of the DNase-treated RNA was run on an agarose gel, quantified and stored at -80°C.

5.1.3 Checking RNA samples for DNA contamination

5 To verify the absence of genomic DNA from the RNA samples, PCR was carried out using primers that amplify the β -tubulin gene (SEQ ID Nos. 77 and 78). In the absence of a reverse-transcription step, only gDNA will be detected and thus any gDNA contamination will be revealed. The following reaction mixture was set up:

10 12.5 μ l 2x ReddyMix PCR mastermix (AB Igene)
1 μ l each primer (5 pmol)
template gDNA (1.5-4 μ g /ml)
nuclease-free water to give a final volume of 25 μ l

15 The reactions were run using the following conditions on a Biometra personal PCR cycler (Thistle Scientific Ltd, DFDS House, Goldie Road, Uddington, Glasgow, G71 6NZ):-

Step1	95°C	5min
Step2	90°C	1min
20 Step3	51°C	1min
Step4	68°C	1min
Step5	68°C	10min
Step6	4°C	Hold

40 cycles steps 2-4

25 If a PCR product was observed, genomic DNA was present and the sample was DNase-treated again. If the PCR was negative, no DNA was present in the sample.

5.1.4 Preparation of cDNA

300 μ g DNA-free RNA and 3 μ l oligo (dT) (100 ng/ μ l) were added to an RNase-free 0.5 ml microcentrifuge tube, and made up a total volume of 42 μ l with DEPC-treated water.

Samples were mixed and incubated in a heat block at 65°C for 5 min and then slowly cooled to room temperature. 2 µl Ultrapure dNTPs (10 mM each, Clontech), 1 µl stratascript reverse transcriptase (Stratagene) and 5 µl 10X reverse transcriptase reaction buffer were then added. The samples were incubated at 42°C for 1h, denatured at 90°C for 5 min and then cooled on ice. Samples were dispensed in 5-10 µl aliquots and stored at -20°C.

5.2. Preparation of cDNA from infected mice

5.1.1 Infection of mice with *A. fumigatus* and extraction of tissues.

Mice were infected with *Aspergillus fumigatus* and organs harvested as follows. Thirteen male CD1 mice were injected with the immunosuppressant cyclophosphamide (0.025 g/ml; 200 mg/kg) IV via the tail vein. After 72 hours, twelve mice were injected with 0.15 ml *Aspergillus fumigatus* AF293 conidia (7.5×10^5 /ml). 11 hours after infection, four mice were sacrificed with an overdose of inhaled halothane. The brain, lungs, liver and kidney were removed, frozen by immersion in liquid nitrogen, and stored at -70°C. A further four mice were also sacrificed at 24 and 48 hours after infection.

RNA was prepared from mouse tissues as described for wax moth larvae above (5.1.2 and 5.1.3).

20

5.2.2 Preparation of cDNA from DNA-free RNA.

cDNA was prepared from DNA-free RNA using the Promega Reverse Transcription kit, following the protocol as supplied with the product (Technical Bulletin No. 099, <http://www.promega.com/tbs/tb099/tb099.pdf>). In a modification to the protocol, the 25 cDNA synthesis reaction was incubated for 60 min at 42°C rather than for the suggested 15 min. Samples were stored in 5-10 µl aliquots at -20°C.

5.3 Design and optimisation of primers

Primers were designed against the 2031 OR cDNA sequence using Beacon Designer 2.1 30 (Premier Biosoft, <http://www.premierbiosoft.com>) with the following parameters; Target

Tm = 58 ± 8°C; Length of primers = 16-24; Amplicon length = 75-150 bp. All other settings were default. Care was taken to choose primers that would not form dimers or other secondary structures. Secondary structures of amplicons were calculated using mfold (<http://www.bioinfo.rpi.edu/applications/mfold/old/dna/form1.cgi>) and primer sets giving an amplicon with little or no secondary structure were chosen. The resulting primers are given as SEQ ID Nos. 79 and 80.

5 To determine optimum annealing temp for the primer set, a gradient PCR was run on an Icycler PCR machine (Biorad), using *A. fumigatus* AF293 genomic DNA as a template and the following reaction mixture:

10

112.5 µl Abgene PCR Reddymix
9 µl SEQ ID No. 79; OXRED 2031F6 (5 pm/µl)
9 µl SEQ ID No. 80; OXRED 2031R5 (5 pm/µl)
85.5 µl H₂O
15 9 µl AF293 gDNA (10 ng/ul)

For the negative control, the gDNA was omitted and the amount of water increased correspondingly.

20

For each mix, 25 µl was pipetted into 8 wells on a multiwell plate, and each well run at a different temp (between 50 and 65°C) with the following conditions:

Step1. 95°C – 5 min

Step2. 95°C – 1 min

25

Step3. Gradient 50-65°C – 1.5 min

Step4. 72°C – 1 min

Step5. 72°C – 10 min

Step6. 8°C – hold

30

Steps 2-4 were run for 30 cycles

The PCR products were run on a 2% agarose gel. A single band of the correct size of 148 bp was seen on the gel for all the temperatures, and the optimum was found to be 63°C.

5 5.4 Testing species-specificity of primers

The real-time primers designed above were further tested to ensure that mouse nucleic acid was not amplified using these primers. Four reactions were set up, each containing the following:

10 12.5 µl Abgene Reddymix

1 µl primer SEQ ID No. 79

1 µl primer SEQ ID No. 80

9.5 µl H₂O

and either; 1 µl infected mouse kidney cDNA (50 ng/µl; experimental); 1 µl uninfected mouse kidney cDNA (50 ng/µl; uninfected control); 1 µl AF293 gDNA (10 ng/µl; positive control); 1 µl water (negative control).

The following PCR settings were used:

Step1 95°C – 5 min

20 Step2 95°C – 1 min

Step3 63°C – 1.5 min

Step4 72°C – 1 min

Step5 72°C – 10 min

Step6 8°C – hold

25 Steps 2-4 were run 40 times

The PCR products were run on a 2% agarose gel. *A. fumigatus* genomic DNA gave a band of 148 bp, the expected size, but no bands were seen in uninfected or infected mouse cDNA. These primers therefore appeared to be specific.

5.5 Real-time PCR to detect expression in infected larvae

PCR reactions were set up using the Biorad iQ SYBR green supermix as follows:

5 14 µl Primer SEQ ID No. 79
14 µl Primer SEQ ID No. 80
175 µl SYBR mix
133 µl H₂O

10 Four reactions were set up containing 72 µl of the above mix and either; 3 µl H₂O; 3 µl uninfected larvae cDNA (50 ng/µl); 3 µl AF293 gDNA (5 ng/µl); or 3 µl infected larvae cDNA (50 ng/µl) were added. 3 x 25 µl aliquots of each reaction were aliquoted into an Abgene multiwell plate, the plate sealed with optical sealing tape (Biorad), then placed in a Biorad Icycler real-time PCR machine. Reactions were run with the following conditions:

15 Step1. 95.0°C 3 min
Step2. 95.0°C 30 sec
Step3. 63.0°C 30 sec

Data collection and real-time analysis enabled.

20 Step4. 72.0°C 15 sec
60 cycles of steps 2-4.
Step5. 95.0°C 30 sec
Step6. 50.0°C 30 sec
Step7. 50.0°C 10 sec

25 90 cycles of step 7 with setpoint temperature increased by 0.5°C after each cycle starting with cycle 2. Melt curve data collection and analysis enabled.

Results are shown in Tables IV and V. Expression of 2031 OR was demonstrated in both Af293 cDNA (C_t = 25.8) and in infected larvae (C_t = 32.3). Therefore, the message is expressed both in *A. fumigatus* cultures and in *A. fumigatus* from infected larvae. The negative and uninfected larvae controls give only primer dimers and non-specific products.

Table IV. PCR Quantification Spreadsheet Data for SYBR-490

Well	Identifier	Ct
C08	infected larvae (50ng)	33
C09	infected larvae (50ng)	32.4
C10	infected larvae (50ng)	31.4
D03	Negative	51.3
D04	Negative	N/A
D05	Negative	55.6
H03	uninfected larvae	36.4
H04	uninfected larvae	N/A
H05	uninfected larvae	N/A
H08	<i>A. fumigatus</i> gDNA (5ng)	25.8
H09	<i>A. fumigatus</i> gDNA (5ng)	26
H10	<i>A. fumigatus</i> gDNA (5ng)	25.8

5 Data Analysis Parameters: Calculated threshold was replaced by the user selected threshold 7.4.; User selected baseline cycles were 2 to 10.

Table V. Melt Curve Analysis Spreadsheet Data for SYBR-490

Well	Well Identifier	Peak ID	Melt Temp
C8	infected larvae (50ng)	C8.1	88.5
C9	infected larvae (50ng)	C9.1	88.5
C10	infected larvae (50ng)	C10.1	88.5
D3	Negative	D3.1	78
D5	Negative	D5.1	81.5
		D5.2	77.5
H3	uninfected larvae	H3.1	81.0

H5	uninfected larvae	H5.1	78.0
H8	<i>A. fumigatus</i> gDNA (5ng)	H8.1	89.0
H9	<i>A. fumigatus</i> gDNA (5ng)	H9.1	89.0
H10	<i>A. fumigatus</i> gDNA (5ng)	H10.1	89.0

Melt Curve Analysis Parameters; Threshold for automatic peak detection was set at 2.64.

5.6 Real-time PCR to detect expression in infected mouse kidney cDNA.

5

Real-time experiments similar to those described in 5.5 using 1 μ l of infected mouse cDNA showed no amplification (data not shown). The experiment was therefore carried out using an increased amount of infected mouse cDNA with the following conditions:

10 18 μ l Primer SEQ ID No. 79

18 μ l Primer SEQ ID No. 80

225 μ l SYBR mix

99 μ l H₂O

15 Four reactions were set up containing 60 μ l of the above mix and either; 15 μ l H₂O; 3 μ l uninfected mouse kidney (50 ng/ μ l) + 12 μ l H₂O; 15 μ l infected mouse kidney – 48h post-infection (50ng/ μ l); or 3 μ l AF293 cDNA (5ng/ μ l) + 12 μ l H₂O were added. 3 x 25 μ l aliquots of each reaction were aliquoted into an Abgene multiwell plate, the plate sealed with optical sealing tape (Biorad), then placed in a Biorad Icyler real-time PCR machine.

20 Reactions were run with the following conditions:

Step1. 95.0°C 3 min

Step2. 95.0°C for 30 sec

Step3. 63.0°C for 30 sec

25 Data collection and real-time analysis enabled.

Step4. 72.0°C for 15 sec

60 cycles of steps 2-4.

Step5. 95.0°C for 30 sec
 Step6. 50.0°C for 30 sec
 Step7. 50.0°C for 10 sec

90 cycles of step 7 with setpoint temperature increased by 0.5°C after each cycle starting
 5 with cycle 2. Melt curve data collection and analysis enabled.

Expression of *A. fumigatus* AF293 2031 OR was seen in cDNA (Ct = 28.8) but only in 2 of
 the 3 infected mouse kidney reactions (Ct values = 34.4, 41.2) (Tables VI and VII). The
 product in the other infected kidney cDNA reaction (well A12) was a primer dimer or a
 10 non-specific product (Tm = 81°C on the melt curve), whereas the correct 2031 OR product
 has a Tm of 88.5°C (Tables VI and VII). The negative and uninfected kidney controls gave
 only primer dimers and non-specific products.

Table VI: PCR Quantification Data for SYBR-490

Well	Identifier	Ct
A10	infected kidney (250ng)	34.4
A11	infected kidney (250ng)	41.2
A12	infected kidney (250ng)	38
D02	Negative	50.3
D03	Negative	54.6
D04	Negative	46.2
H02	uninfected kidney	52.8
H03	uninfected kidney	54
H04	uninfected kidney	51.8
H10	AF293 (5ng)	28.7
H11	AF293 (5ng)	28.7
H12	AF293 (5ng)	30

Calculated threshold was replaced by the user selected threshold 5.4. User selected
 baseline cycles were 2 to 10.

Table VII. Melt Curve Analysis Spreadsheet Data for SYBR-490

Well	Well Identifier	Peak ID	Melt Temp
A10	infected kidney (250 ng)	A10.1	88.5
A11	infected kidney (250 ng)	A11.1	88.5
A12	infected kidney (250 ng)	A12.1	81.0
D2	Negative	D2.1	79.0
D3	Negative	D3.1	78.0
D4	Negative	D4.1	78.0
H2	uninfected kidney	H2.1	78.5
H3	uninfected kidney	H3.1	77.5
H4	uninfected kidney	H4.1	90.5
H10	AF293 (5ng)	H10.1	88.5
H11	AF293 (5ng)	H11.1	88.5
H12	AF293 (5ng)	H12.1	88.5

Threshold for automatic peak detection was set at 2.09.

5 *A. fumigatus* 2031 OR is therefore clearly expressed during infection of wax moth larvae. 2031 OR is only expressed at a very low level during infection of mouse kidney, since increased amounts of template had to be used to give a signal. The expression during infection suggests that the gene product may be a suitable target for an anti-fungal drug.

10 Example 6. Expression of recombinant 2031 OR and/or fragments

Recombinant proteins or fragments were expressed to enable detailed study of function and as the starting point for the development of a high-throughput screen for inhibitory compounds.

15

6.1 Production of cDNA constructs

PCR was carried out using cDNA prepared as described above to generate polynucleotides encoding 2031 OR sequence essentially corresponding to SEQ ID No. 3. PCR reactions

were carried out using the following reaction mixture and conditions. All Reagents were present in the KOD kit (Novagen).

2.5 μ l 10x PCR Buffer
5 5 μ l dNTPs (2mM)
2 μ l MgSO₄ (25mM)
1 μ l primer A (5 pmol) (SEQ ID No. 55; SL_OxXa30F5)
1 μ l primer B (5 pmol) (SEQ ID No. 56; SL-OxXa30R7)
1 μ l template cDNA
10 11.5 μ l nuclease-free water
1 μ l KOD Polymerase

PCR reactions were run using the following conditions:-

15 Step1 94°C 5 min
Step2 94°C 1 min
Step3 59.3°C 1 min
Step4 68°C 1 min 30sec
Step5 68°C 10 min
20 Step6 10°C Hold

40 cycles of steps 2-4 were carried out and the PCR products were purified using Qiagen's QIAquick PCR Purification Kit (Qiagen Ltd, Boundary Court, Gatwick Road, Crawley, West Sussex, RH10 9AX, UK) according to the manufacturers instructions. The purified 25 PCR products were examined on agarose gels.

cDNA fragments were then cloned in to the pET30 Xa/LIC vector (Novagen), transformed into Nova Blue chemically competent *E. coli* cells, and plated on to a prewarmed kanamycin (+) selection plate. After an overnight incubation at 37° C, kanamycin-resistant colonies were selected and grown up in kanamycin containing LB 30 medium. Plasmid DNA was isolated using the Plasmid Mini Kit (Qiagen). Confirmation of

the presence and correct orientation of the inserts was determined by restriction analysis and sequencing of the construct.

Purified plasmid DNA, which had been confirmed to be of the correct sequence and orientation, was transformed into chemically competent BL21 Star (DE3) One Shot *E. coli* cells and grown overnight at 37° C. 2 ml of an over-night culture were used to inoculate 5 100 ml of LB, 30 µg/ml kanamycin, and the cultures incubated at 37° C, 220 rpm until the cell density reached an optical density of 0.6 (approximately 3 hours). Expression of the recombinant protein was then induced with IPTG (1mM) for 5 hours.

Bacteria were harvested by centrifugation at 4500 rpm for 10 minutes and the pellets 10 lysed in lysis buffer (10 ml Bugbuster (Novagen), 10 µl Benzonase (Novagen), 0.4 µl lysozyme (Novagen) and 100 µl 1M imadazole for 20 minutes at room temperature. Cells were then spun down at 16000g for 20' at 4° C and the supernatant, containing soluble recombinant protein, removed to a clean tube.

Supernatant was added to prewashed Ni-Nta resin at a concentration of 5-10 mg 15 protein per ml of resin and allowed to bind for 1 hour at 4° C. Protein-resin mix was then poured into a column, washed twice in 4 ml of wash buffer (2.5 ml 1M phosphate buffer pH8 , 6.25 ml 4M NaCl, 1 ml 1M Imidazole pH8, 0.5 ml 10% Tween 20; made up to 50 mls in n.H₂O) and then eluted in 4x 0.5 ml fractions with elution buffer (250 µl 1M Phosphate Buffer pH8, 625 µl 4M NaCl, 1.25 ml 1M Imidazole pH8, 50 µl 10% Tween 20, Made up to 5 mls in n.H₂O). Fractions containing purified protein were detected by 20 SDS-Page and Western blotting using an S-tag HRP conjugate (Novagen). Fractions containing purified recombinant protein were concentrated using YM10 columns (Millipore)

Figure 3A shows the induction of recombinant 2031 OR expression by IPTG over 24 25 hours. Protein samples were taken at time points, run on an SDS-PAGE gel and stained with coomassie. By 1 hr a band of the correct size was clearly induced compared to the uninduced samples. The amount of protein increased with longer induction times. Figure 3B shows a coomassie stained gel of the purified recombinant 2031 OR. Alternative expression systems can be used for expression in bacteria, such as the glutathione S- 30 transferase or mannose-binding fusion-protein system.

Recombinant fragments of other 2031 ORs can be generated using the primer pairs and templates described in Table VIII, or similar primers and other 2031 OR listed in Table III.

5 Table VIII. Primer pairs for the recombinant expression of 2031 OR family proteins

Species	Template	Primer A	Primer B
<i>A. fumigatus</i>	SEQ ID No. 2	SEQ ID No. 55	SEQ ID No. 56
<i>A. fumigatus</i>	SEQ ID No. 5	SEQ ID No. 57	SEQ ID No. 58
<i>A. fumigatus</i>	SEQ ID No. 7	SEQ ID No. 59	SEQ ID No. 60
<i>A. nidulans</i>	SEQ ID No. 9	SEQ ID No. 61	SEQ ID No. 62
<i>C. albicans</i>	SEQ ID No. 11	SEQ ID No. 63	SEQ ID No. 64
<i>M. grisea</i>	SEQ ID No. 21	SEQ ID No. 65	SEQ ID No. 66

Example 7. Oxidoreductase assay and inhibitor screening

7.1 Oxidoreductase assay

10 The assay for 2031 OR is based on methods described by Abramovitz & Massey (1976, *J. Biol. Chem.* 251: 5321-5326) and Stott et al. (1993, *J. Biol. Chem.* 268: 6097-6106) and is based upon the ability of this enzyme to oxidise the pyridine nucleotides NADH and/or NADPH. The peak of absorbance for the reduced form of these cofactors (i.e. NADH and NADPH) is at a wavelength of 340 nm whereas the oxidised forms of the cofactors (i.e. NAD⁺ and NADP⁺) do not absorb at this wavelength. Conversion of NAD(P)H to NAD(P)⁺ can therefore be monitored spectrophotometrically at a wavelength of 340 nm. A similar assay can be employed for all oxidoreductases that use NADH or NADPH as a cofactor.

20 Assays were carried out in 96-well plates. To each well was added the following; Recombinant 2031 OR (10-1000 ng); 40 µl of 125-2500 µM NADPH; 1 µL 100 mM cyclohexeneone or other substrate, and the volume made up to 200 µL with 0.1 M potassium phosphate pH 7.0. Samples were incubated at room temperature and absorbance measurements were taken at 340 nm every 30 seconds for 10 min. The change in absorbance was expressed as nmoles NADPH oxidised, using the molar extinction

coefficient of NADPH and NADH at 340nm of 6270 (i.e., a 1M solution has an optical density of 6270 at this wavelength).

Initial experiments with a variety of potential substrates for recombinant 2031 OR showed that the protein had a functional dehydrogenase activity and determined that 5 cyclohexenone was a better substrate than menadione, duroquinone or N-ethylmaleimide. This is illustrated in figure 5. Final concentrations in the assay were as follows: 500 μ M substrate, 1 μ g/200 μ L 2031 OR, 120 μ M NADPH.

Although the physiological substrates of 2031 OR remain to be determined, generic 10 oxidoreductase substrates such as ferricyanide, methylene blue, phenazine methosulphate and 2,6-dichlorophenolindophenol may also be used to assay for oxidoreductase activity.

Screens for inhibitors of 2031 OR can be carried out using the assay described above modified by the addition of putative inhibitor substances to the reactions and decreasing the amount of potassium phosphate buffer. Assays can be carried out in 384- or 1536-well plates to increase throughput of the screen.

15

7.2 High-throughput screen for the identification of 2031 OR inhibitors

2031 OR inhibitors were identified by means of a high-throughput screen. The following reagents were prepared:

Assay plates: Compounds to be tested were dissolved in 100% DMSO (polypropylene 20 vessels), diluted in water and loaded into 384 square well polystyrene plates (10 μ l/well). The final DMSO concentration in all assay wells was 5%v/v.

β NADPH (tetrasodium salt)/2-cyclohexen-1-one reagent; Solutions of NADPH (1.2917 mM in 100 mM potassium phosphate buffer, pH7.0) and 2-cyclohexen-1-one (10 mM in 100 mM potassium phosphate buffer, pH7.0) were prepared on the day of the assay and 25 combined in a ratio of 1 part of 2-cyclohexen-1-one solution to 9 parts NADPH solution. Final assay well concentrations for NADPH and 2-cyclohexen-1-one were 465 μ M and 400 μ M respectively.

2031 OR enzyme: Recombinant enzyme was prepared as described in Example 6 and desalted as follows: 2.5 ml of eluted protein was loaded onto on to a PD10 column (Amersham) equilibrated with 25 ml of 0.1 M KPO₄ pH7. The protein was then eluted with 3.5 ml of 0.1 M KPO₄ pH7. Aliquots of the protein were stored at -80°C. For the

iscreen, protein was typically diluted to 5 to 11.25 μ g/ml in 100 mM potassium phosphate buffer, pH7.0.

Stop reagent: 0.4 M NaOH in water.

5 The Km for 2-cyclohexen-1-one, the substrate for 2031 OR in the screening assay, was determined to be 100 μ M. To give an increased signal, the screen was carried out using 2-cyclohexen-1-one at 4 times Km. The kinetics of the screen over the prescribed incubation time were such that reaction progress curves were both linear with time and protein concentration. The Z' value for the screen was equal to 0.77 and thus fully acceptable
10 (Zhang et al., 1999, J. Biomolecular Screening, 4, 67-73). Consistency of signal between wells on plates, plate to plate and screen run to screen run were also acceptable for an HTS regime.

Assays were carried out using Tecan Freedom, Tecan TeMo and PerkinElmer Minitrak robots together with a ThermoLabsystems multidrop 384 and a Tecan Safire automated plate reader. 20 μ l of enzyme followed by 20 μ l NADPH/2-cyclohexen-1-one solution were added to wells of the microtitre plates containing test compounds. 20 μ l of 100 mM potassium phosphate buffer, pH7.0 was used for a duplicate set of plates for background no-enzyme controls; DMSO (diluted in the same way as solubilised compound stocks) was used for no-compound controls. Plates were incubated at room temperature for
15 30 minutes after which 25 μ l of 0.4 M NaOH stop reagent was added. Plates were read at 340 nm on a Tecan Safire plate reader and data processed using 'in-house' created Excel spreadsheets to convert raw data into percent inhibition data. Secondary screens were carried out to measure dose response data for selected compounds, using essentially the same protocol as the primary screen. The secondary screen used the Excelfit version 3
20 software (IDBS), with sigmoidal model 606, to graph appropriate inhibition values and determine IC50 data for compounds tested. Figure 6 shows typical results for 2 inhibitory compounds (A and B) identified by the primary screen and then assayed in the secondary screen.

Identification of the correct stop reagent for the HTS assay was not trivial. Initially, 25 a chemical inhibitor of the system was sought to terminate the reactions in a pH independant manner, but it was found that NaOH offered more benefits than originally

anticipated, in that it not only overcame the buffering in the reaction to fully terminate the reaction, but also afforded a much greater protection for un-reacted NADPH. It is known that high levels of NaOH convert NADP, a product of the reaction which does not absorb at 340 nm, to a fluorescent product, which would interfere with the 340 nm readings taken
5 (Passonneau and Lowry, 1993, Enzymatic analysis, a practical guide, pp.3-21 and p381. 1993 The Humana Press Inc. NJ USA.). Therefore, the NaOH level used in the HTS assay was chosen such that the amount of fluorescence from NADP conversion was reduced to an insignificant level, whilst fully terminating the reaction. The greater stability of the NADPH afforded by the use of NaOH meant that instead of immediate plate readings,
10 plates could be read up to at least 20 hours post reaction termination (no further extended time points were investigated). This was an obvious advantage in that larger screens could be run. Plates stored for spectrophotometric reading were sealed with self adhesive film and stored in the dark.

15 Example 8. Method for detecting fungal infection

The sequences described in the invention were exploited to diagnose fungal infections. Samples from patients potentially carrying an infection with *A. fumigatus*, *A. nidulans*, or
20 *C. albicans* or rice leaves or stem potentially infected with *M. grisea*, or of alfalfa infected with *C. trifolii*, or wheat infected with *F. graminearum*, *F. sporotrichioides*, or *M. graminicola*, or other organisms, are processed to extract DNA using the DNAeasy Tissue kit or QIAamp DNA Blood Mini kit (Qiagen, Crawley, UK), although other DNA preparation methods are available and suitable.

Once DNA has been prepared, PCR reactions are set up as follows:

25

Reaction mix:

12.5 μ l 2x ReddyMix PCR mastermix (ABgene)
1 μ l primer A (5 pmol)
1 μ l primer B (5 pmol)
30 5 μ l template DNA
5.5 μ l nuclease-free water

Suitable primer pairs are given in the table IX below:

Table IX. Primer pairs for PCRs to diagnose fungal infection.

Species	Template	Primer A ¹	Primer B ¹
<i>A. fumigatus</i>	SEQ ID No. 1	SEQ ID No. 67 (94)	SEQ ID No. 68 (286)
<i>A. fumigatus</i>	SEQ ID No. 4	SEQ ID No. 69 (239)	SEQ ID No. 70 (450)
<i>A. fumigatus</i>	SEQ ID No. 7	SEQ ID No. 71 (1097)	SEQ ID No. 72 (1271)
<i>C. albicans</i>	SEQ ID No. 11	SEQ ID No. 73 (103)	SEQ ID No. 74 (277)
<i>M. grisea</i>	SEQ ID No. 20	SEQ ID No. 75 (385)	SEQ ID No. 76 (620)

5 Figures in brackets after SEQ ID No. indicate the base in the template at which the primer starts.

10 Appropriate controls include; (i) template DNA but no primers; primers but no template (negative controls); (ii) cDNA encoding fungal 2031 OR or DNA from cultured fungi instead of patient DNA (positive control).

PCR reactions are run as follows:

Step1	95°C	5 min
Step2	95°C	1 min
15 Step3	53°C	1 min 30sec
Step4	72°C	1 min 30sec
Step5	72°C	10 min
Step6	4°C	Hold

20 30 cycles of steps 2-4 are carried out and the PCR products examined on agarose gels. The production of a band of the correct molecular weight is diagnostic of the presence of the particular fungus. It may be additionally necessary to carry out diagnostic restriction digests of the PCR products. If necessary, PCR products are subcloned into a vector, such as pGEM-Teasy (Promega), and sequenced to verify that the PCR products are from the 25 appropriate fungus.

Alternatively, the presence of an infection with *A. fumigatus*, *A. nidulans*, *C. albicans* or *M. grisea*, *C. trifolii*, *F. graminearum*, *F. sporotrichioides* or *M. graminicola*, or other organisms is detected by means of antibodies raised against the fungal protein. One suitable means is the use of a capture ELISA. Here, microtitre plates are coated with a 5 monoclonal antibody raised against the fungal protein. Then the plates are incubated with diluted patient samples, or appropriate protein extracts of samples (particularly if the samples are biopsies or plant tissues). Plates are then incubated with a polyclonal antibody (again against the fungal protein). Finally, binding of the second antibody was detected by means of an enzyme-coupled or fluorescently-labelled antibody directed against the 10 polyclonal. In practise, two monoclonal or polyclonal antibodies or various combinations may be used.

Example 9. Production of an antibody

15 Antibodies against the fungal 2031 ORs will be of considerable use as diagnostic reagents (see example 8 above). As an immunogen, recombinant domains are used (as described in Example 6). Alternatively, synthetic proteins encoding regions either unique to the individual 2031 ORs, or likely to provide cross-reactivity within a set of ORs, a set of species, or a range of genera are used. Peptides may need to be conjugated to carrier 20 proteins before immunization.

Preimmune sera from animals to be immunised are screened against the immunogen to ensure that there is no endogenous cross reactivity. Animals (typically sheep, rabbits or mice) are then immunised. For polyclonal antibody production, the resulting sera is affinity 25 purified using the immunogen cross-linked to a chromatography matrix. Alternatively, purification of the antibody fraction from the serum, e.g. using protein G or protein A cross-linked to a matrix, may be sufficient. Monoclonal antibody production proceeded by methods familiar to those skilled in the art.

The specificities of the resulting polyclonal and/or monoclonal antibodies are checked by ELISA and/or western blotting using the immunogen, related constructs or 30 whole cell lysates and extracts as targets. Negative controls, such as other ORs, different

constructs or different species are also employed to test specificity and/or to determine the range of species and/or genus cross-reactivity.

Example 10. Production of fungi with 2031 OR genes functionally disabled.

5

A BAC (bacterial artificial chromosome) clone library containing the *A. fumigatus* genome, partially digested with BamHI and inserted into the vector pBACe3.6 was purchased from the Sanger Centre, Cambridge, UK. The BAC clone containing the gene to be inactivated is identified by bioinformatics (BLAST searching of Sanger BAC and related databases) and the glycerol stock of the clone grown up in 50 ml LB, 20 µg/ml chloramphenicol at 37°C overnight. The overnight culture is centrifuged at 4,500 rpm for 15 min. The bacterial pellet is resuspended in 4 ml of Buffer P1 (Qiagen plasmid miniprep kit) and then 4 ml of buffer P2 (Qiagen plasmid miniprep kit, lysis buffer) is added and mixed gently by inverting 3-6 times. Proteins and genomic DNA are precipitated by adding 10 4 ml of buffer P3 (Qiagen plasmid miniprep kit, neutralizing buffer) and incubating on ice for 10 minutes. Following the centrifugation of the mixture at 4500 rpm for 30 min, the supernatant is transferred into a 50 ml falcon tube, an equal volume of phenol/chlorophorm (1:1) mixture is added, and the mixture centrifuged for 15 min at 4500 rpm. The supernatant is then transferred into an Oakridge tube and 0.7 volumes isopropanol are 15 added. After mixing, the tube is centrifuged at 10,000 rpm (Beckman centrifuge, rotor JA-17) for 30 min at 4°C. The resulting pellet is washed with 2 ml 70% ethanol at the same speed. The resulting BAC DNA is resuspended in 100 µl buffer EB.

The transposition reaction is carried out as follows. 7 µl purified BAC, 1 µl transposon pZVK2 (an engineered plasmid the sequence of which is given as SEQ ID No. 25 81), containing the mosaic ends of pMOD2 (Epicenter), a kanamycin resistance gene and a Zeocin resistance gene under the control of fungal promoter) and 1 µl EZ:TN transposase (Epicenter) are incubated at 37°C for two hrs after which 1 µl stop solution (1% SDS) is added and the mixture heated to 70°C for 10 minutes. Electrocompetent GeneHogs *E. coli* cells (Invitrogen) are then transformed with the transposed BAC, the 30 cells plated onto LB agar, 25 µg/ml kanamycin, 20 µg/ml chloramphenicol, and plates incubated overnight at 37°C.

At least 96 colonies are picked and grown up in 96-well plates in 2xLB (double concentrated LB), 20 µg/ml chloramphenicol, at 37°C overnight. BAC DNA is then purified using the Millipore montage 96 BAC KIT using a MWG ROBOSEQ 4200 robot. BACs containing the transposon inserted into the gene of interest are identified by PCRs both spanning the gene of interest and extending from the transposon into the BAC. Insertion into the gene of interest is manifested as an increase in product size. Southern blots are also carried out to ensure that the transposon has only inserted once into the BAC.

The BAC is then linearised using a restriction enzyme determined to cut in the vector backbone but not the BAC DNA, and used to transform *A. fumigatus* strain Af293. *A. fumigatus* (haploid) protoplasts are prepared using 5% Glucanex (Novo Nordisk A/S) solution (in 0.6 M KCl) and shaking for 2 h at 80 rpm in 30°C. The protoplasts are washed with 0.6 M KCl and then with STC (Sorbitol, Tris, CaCl₂). The washed protoplasts are diluted in STC to 10⁵/ml and 100 µl transferred into 14 ml falcon tubes. 7 µl of linearised BAC are added to the tube and the whole mixture incubated on ice for 20 min. Transformation is carried out by adding 200 µl of PEG 8000 solution (60%w/v, pH 7.5) drop-wise over 2 min and then adding 800 µl PEG. The mixture is left at room temperature for 20 min. Transformed protoplasts are washed with STC, resuspended in 1 ml STC, spread onto CM-sorbitol- Zeocin (250 µg/ml) plates and incubated at 37°C.

After 4-10 days of incubation, zeocin resistant colonies are picked and checked for presence of the knocked-out gene by PCR using primers which specifically amplify the whole gene of interest. Usually 10-20 transformants are checked. The ectopic integration of the BAC gives two bands by PCR, one for the endogenous gene and one for the BAC/transposon construct, which has a higher molecular weight. Replacement of the endogenous gene with the transposon-modified gene results in a single band of higher molecular weight by PCR. If none of the transformants show the disrupted endogenous gene, the gene of interest may be essential, with the knock-out cells having died and only cells where replacement is unsuccessful surviving. In this case, the transformation is carried out on diploids using the same method of transformation. Essentiality of the gene is then tested by rehaploidisation, and examining the segregation pattern in haploids.

Example 11. Rescue of MycoBank transformant with the 2031 oxidoreductase gene.11.1 Preparation of the 2031 OR construct

The 2031 OR gene with NheI overhangs was prepared by PCR using the primer pair;

5 SEQ ID No 98 and SEQ ID No. 99.

PCR Reaction: 2.5 μ l 10x PCR buffer

0.5 μ l dNTPs

2 μ l MgSO₄

10 1 μ l forward primer (SEQ ID No. 98)

1 μ l reverse primer (SEQ ID No. 99)

1 μ l gDNA

Made up to 25 μ l with n.H₂O

15 PCR Cycle: (1) 94° C, 5'; (2) 94° C, 1'; (3) 50° C, 1'; (4) 68° C 1'30s; (5) 68° C, 10'; (6) 8° C, Pause; Cycles 2 to 4 were repeated 40 times

20 The finished amplicon (~1260 bp) was run out on a 1% agarose gel, the appropriate band was cut out and purified using the Qiagen gel extraction kit and eluted off the column in 30 μ l H₂O. The amplicon was ligated into pGEM Teasy using the following reaction mixture:

25 5 μ l 2x ligation buffer

1 μ l pGEM Teasy vector

either 1, 2 or 3 μ l of insert

1 μ l T4 DNA ligase

Reaction made up to 10 μ l with n.H₂O

The ligation reaction was incubated overnight in the fridge

30 2 μ l of each ligation reaction was transformed by heatshock at 42°C into promega 96 select cells. After transformation, cells were incubated in SOC for 1 h at 37°

C, 220 rpm. 50 and 150 μ l aliquots were then spread over LB-Amp (100 μ g/ml), IPTG-Xgal plates and left at 37° C overnight. Positive clones were identified by blue/white screening and were isolated and screened by PCR for correct insertion of the 2031 OR insert using the above primers. Positive clones were sent away to MWG for sequence analysis.

5 **11.2 Cloning of 2031 OR into the CbhB-Zeo vector**

Plasmid DNA for 2031 OR in pGem Teasy (as described in 11.1) was digested overnight at 37° C with NheI. The 2031 OR insert fragment was then gel purified using the Qiagen gel extraction kit and ligated into CbhB-Zeo vector. This vector was constructed from pUC19 with the *A. fumigatus* CbhB promoter and terminator and the zeocin resistance gene.

10 Ligation: 1 μ l of T4 DNA ligase
1 μ l of 10x ligase buffer
1 μ l of CbhB vector (linearised and alkaline phosphatase treated)
1 μ l of insert
6 μ l n.H₂O

15 Ligation reaction was left in the fridge overnight.

20 2 μ ls of each ligation reaction was transformed by electroporation at 2.5 Kvolts, 200 Ω , 25 μ F into Genehog cells. After transformation, cells were incubated in SOC for 1 h at 37° C, 220 rpm. 50 and 150 μ l aliquots were then spread over LB-Amp (100 μ g/ml) plates and left at 37° C overnight. Positive clones were isolated and screened by PCR for the correct insertion of the insert by PCR as above. Positives were sent to MWG for sequence analysis.

11.3 Transformation into Mycobank mutant 2031

The CbhB-Zeo-2031 plasmid was digested with ScaI overnight at 37° C. Linearised plasmid was then run out on a 1% agarose gel and purified using the Qiagen gel extraction kit. Plasmid DNA was eluted in 30 µls of nH₂O.

5 Mycobank mutant 2031 AF293 spores were swollen for 6 h at 37° C, 300 rpm, centrifuged 3500 rpm, 5' and resuspended in ice-cold nH₂O. Spores were spun again, 3500 rpm, 5' then resuspended in 12.5 ml of YED medium and incubated for 1h at 30° C, 100 rpm. Spores were then counted and resuspend in EB buffer to a final concentration of 5x10⁷ spores per ml. 50 µl of swollen spores were then transformed with 1-10 µl of 10 linearised CbhB-Zeo-2031 plasmid DNA at 1 Kvolt, 400 Ω, 25 µF. Spores were transferred in to YED buffer and left for 90' at 37° C, 100 rpm. 100 and 200 µl aliquots were then spread out on to CM-Zeocin (200 µg/ml) plates and incubated at 37° C for 2-3 days.

15 Positive transformants on the CM-Zeo plates were picked into 5 ml of SAB broth and incubated overnight at 37° C, 220 rpm. Biomass was then filtered and collected on to Whatman paper. DNA was extracted using the Fast prep kit and cleaned up over a Qiagen miniprep DNA column. DNA was eluted off column in 30 µl of nH₂O.

PCR Screening was performed using the following primer sets:

Set A: Ox7race_for (SEQ ID No. 51) + CbhBtR (SEQ ID No. 100)
20 Set B: Ox6race_rev (SEQ ID No. 50) + CbhBpF (SEQ ID No. 101)

PCR Reaction: 12.5 µl 2x Reddy mix

1 µl each primer, from set A or B

1 µl plasmid DNA

25 Made up to 25 uL with water

PCR Cycle: (1) 94° C, 5'; (2) 94° C, 1'; (3) 56° C, 1'; (4) 72° C 1'30s; (5) 72° C, 10'; (6) 8° C, Pause; Cycles (2) to (4) were repeated 40 times

30 Positive transformants which were demonstrated to have CbhB-Zeo-2031 in Mycobank mutant 2031 were put through the rehaploidation process to test their ability to

grow on hygromycin compared with the untransformed mycobank mutant 2031. We found that the lethal 2031 phenotype was rescued by the insertion of the CbhB-Zeo-2031 plasmid, confirming the essentially of 2031 OR.

5 The reader's attention is directed to all papers and documents which are filed concurrently with or previous to this specification in connection with this application and which are open to public inspection with this specification, and the contents of all such papers and documents are incorporated herein by reference.

10 All of the features disclosed in this specification (including any accompanying claims, abstract and drawings), and/or all of the steps of any method or process so disclosed, may be combined in any combination, except combinations where at least some of such features and/or steps are mutually exclusive.

15 Each feature disclosed in this specification (including any accompanying claims, abstract and drawings), may be replaced by alternative features serving the same, equivalent or similar purpose, unless expressly stated otherwise. Thus, unless expressly stated otherwise, each feature disclosed is one example only of a generic series of equivalent or similar features.

20 The invention is not restricted to the details of the foregoing embodiment(s). The invention extends to any novel one, or any novel combination, of the features disclosed in this specification (including any accompanying claims, abstract and drawings), or to any novel one, or any novel combination, of the steps of any method or process so disclosed.